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ABSTRACT 
 
 Ginseng is one of the most commonly consumed herbal medicines in the 
world. Consumption is highest in females, thus my studies purpose was to define 
the concentration responsive effects of North American alcoholic and aqueous 
ginseng extracts on preimplantation development in vitro, and on pregnancy and 
post-partum development in the mouse. Two-cell embryos from female mice 
were cultured with five different concentrations of both extracts, ginsenosides 
Rb1, Rg1 and Re, a combinatorial ginsenoside solution and a polysaccharide 
fraction. Embryonic development and recovery from treatment was assessed. To 
investigate in vivo effects of ginseng extracts, females were gavaged with 50 
mg/kg and 500 mg/kg of either extract (treatment), gavaged water (sham) or not 
gavaged (control) for two weeks prior to mating and throughout gestation. 
Gestation period, litter size and pup growth were evaluated. The results 
demonstrate that typical ginseng consumption levels do not adversely affect 
fertility or pregnancy in the mouse, however direct exposure to ginseng extract in 
vitro is detrimental to preimplantation development. 
 
Key words: mouse, preimplantation development, ginseng, ginsenoside, North 
American ginseng, pregnancy, post-partum development, concentration-
dependent developmental blockade, gavage, women 
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Introduction 
1.1 Rationale - Overview 
Herbal medicinal products are a growing market due to their increased 
integration into peoples every day lives. In the United States (US), their 
consumption has increased by 380% in the general population between 1990 and 
1997 (Eisenberg et al. 1998). Additionally, in 1994 the total US sale of herbal 
products was $4 billion (Brevoort 1998). Among these popular herbal remedies is 
ginseng, whose consumption and inclusion as part of a healthy diet is on a 
dramatic rise due to its many purported health benefits, making it one of the 10 
most commonly used herbal medicines in the United States (Bent and Ko 2004).  
Ginseng is an herb in the Araliaceae family and is a species in the genus Panax, 
which means, “all healing” and “longevity”, and while its medicinal properties 
have been appreciated in Asia for over 2000 years, it is now becoming 
increasingly important across the world, specifically in North America (Chu et al. 
2009).  
Research focused on investigating the therapeutic effects of ginseng has 
considerably increased due to its ever-growing popularity as an herbal remedy.  
Research is required to ensure that human consumption of ginseng is safe and to 
define the mechanisms underlying its beneficial effects. Studies have 
demonstrated that ginseng extracts are composed of many compounds with 
unique and beneficial influences on various body systems, including the 
cardiovascular system, nervous system and the reproductive system (Attele et al. 
1999). However, as herbal remedies are usually deemed harmless because they 
are “natural”, this does not in any way ensure that normal levels of consumption 
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of these products are safe (De Smet et al. 2004). In a US survey conducted in 
2001, 9.1% of 242 pregnant women questioned declared use of herbal medicinal 
products during their current pregnancy, and 7.5% were using these supplements 
at least weekly. The most commonly used products were garlic, aloe, chamomile, 
peppermint, ginger, Echinacea, pumpkin seed and ginseng (Gibson et al. 2001). 
In Asia, up to 10% of women have reported use of ginseng through out their 
pregnancy (Chin 1991). With more women of reproductive age taking herbal 
supplements, it is important to investigate ginseng’s effect and safety on 
preimplantation development and pregnancy.  
To date, research investigating ginseng’s impact on reproductive function 
has demonstrated a positive effect on sperm motility (Zhang et al. 2006), but also 
lower morphological scores for in vitro treated rat and mouse embryos than for 
those cultured in a normal environment (Chan et al. 2003, 2004; Liu et al., 2005a, 
2005b, 2006). This later outcome is quite controversial since Lee et al. 2008 
found that treatment of early rat embryos with individual ginsenosides caused 
either no significant change to the morphological scores within the organogenic 
parameters used, and in some cases actually improved them. Ginseng may also 
protect mouse embryos from oxidative stress due to ethanol-induced 
teratogenesis during embryonic organogenesis via activation of embryonic 
antioxidant enzyme defense systems (Lee et al. 2009). In addition, very recent in 
vivo studies have shown that when administering 20, 200 and 2000 mg/kg/day 
(2000 mg/kg/day being ≈200 times the recommended clinical dose) of Korean 
Red Ginseng Extract to females for two weeks before mating and through out 
gestation, that maternal weight, feeding, embryonic implantation and fetal growth 
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were not significantly affected (Shin et al. 2010). While research in this field is 
advancing quickly, it is important to establish whether consumption of all ginseng 
extracts are safe during pregnancy and what effects, if any, direct exposure to 
these extracts may have on preimplantation development. Furthermore, due to so 
much variability between the compounds found in different ginseng products 
(Liberti and Der Marderosian 1978), it is important to study the effects of different 
ginseng species and extracts on reproduction, which is why the aqueous and 
alcoholic extracts produced from North American ginseng (NAG) are used in this 
research.  
Addressing these concerns were the primary purpose of my study. I 
investigated the effects of aqueous (AQ) and alcoholic (ALC) NAG extracts and 
individual ginsenosides and polysaccharides on preimplantation development in 
vitro. I also investigated the influences of both ginseng extracts on fertility, 
pregnancy and post-partum development in the mouse. I have applied my studies 
to the mouse since it is a well characterized research model for understanding 
mammalian development. Furthermore, it is critical to conduct animal model 
studies prior to trials applied directly to the human.  
 
1.2 Embryonic Development: From Fertilization to Childbirth 
1.2.1 Preimplantation Development 
Preimplantation development encompasses the developmental period 
from fertilization to embryo implantation into the uterine wall (Watson and Barcroft 
2001). Fertilization occurs in the swollen ampulla of the oviduct, also referred to 
as the fallopian tube in the human, and includes the fusion of a sperm with a 
 4
mature oocyte released from the ovary. The embryo travels down the oviduct 
towards the uterus. The first cleavage division occurs 16-20 hours following 
fertilization and is characterized by an asynchronous doubling of the number of 
cells, producing a short period of time where cell number may not be even. 
Cleavage produces an embryo with two cells of approximately equal size called 
blastomeres (Fujimori 2010). The first major developmental transition that occurs 
during these early stages of development is the zygotic gene activation, where 
the developmental program of the embryo is no longer exclusively directed by 
maternal proteins and transcripts, but by newly expressed genes (Schultz 2002). 
Individual blastomeres are easily distinguished until half way through the 
eight-cell stage in the mouse when compaction, the first morphological event, 
transpires. Compaction is characterized by an increase in cell-cell adhesion due 
to E-Cadherin and tight junction (TJ) formation, (Shirayoshi et al. 1983; Watson 
and Barcroft 2001) causing the membranes of individual blastomeres to be 
indiscernible. Compaction is also linked to the onset of cellular polarization of the 
outer cells of the embryo, (Watson and Barcroft 2001) which form the 
trophectoderm (TE). Additionally, the inner cells give rise to the Inner Cell Mass 
(ICM) (Johnson and McConnell 2004). At the 32-cell stage, multiple small fluid 
filled cavities begin to form in the embryo due to active transport of ions and 
subsequent fluid movement down the ionic concentration gradient across the 
trophectoderm epithelium, a phenomenon known as cavitation. The individual 
cavities fuse together and create the blastocyst cavity, which separates the two 
cells types. The ICM cells are pluripotent and become the embryo proper, 
whereas the TE gives rise to the placenta. These final steps lead to the formation 
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of the blastocyst, which precedes embryo implantation to the uterine wall and is 
the last step of preimplantation development (Enders and Shlafke 1968; Lin et al. 
2001; Watson and Barcroft 2001; Fujimori 2010).  
 
1.2.2  Implantation 
Implantation is the attachment of the embryo to the maternal endometrial 
epithelium and its ensuing invasion into the stroma (Hemberger 2012). The TE, 
previously referred to as the outer cell layer of the embryo, is made up of 
trophoblast cells, and its initial role is to mediate implantation of the blastocyst 
into the uterine wall (Enders and Shlafke 1968). Before invasion by trophoblast 
cells begin however, maternal endometrial stromal cells transform into decidual 
cells and form a dense cellular matrix called the decidua. This physical barrier 
slows embryonic migration toward the mother’s uterine spiral arteries (Kearns 
and Lala 1983) and promotes trophoblast attachment rather than invasion 
(Kliman 2000). The decidualized stromal cell is also a secretory cell and 
expresses new proteins such as prolactin and insulin-like growth factor binding 
protein-1 (IGFBP-1) (Tarantino et al. 1992). After decidualization, the trophoblast 
cell differentiation pathway is altered, and villous trophoblasts are transformed 
into anchoring trophoblasts (Kliman 1994; Kliman 1999) in part due to contact 
with the decidua. Trophoblasts then migrate to the uterus and direct their 
movement toward the maternal spiral arteries where their cellular extensions form 
an anastomosing network around the implantation site. This allows permeation of 
the attachment site with maternal blood via low resistance channels. Finally, 
trophoblasts limit their invasion to the upper third of the uterus and are eliminated 
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after delivery (Strickland and Richards 1992; Cross et al. 1994; Kliman 1994; 
Hemberger 2012).  
While implantation is extremely complex and not all compounds involved 
have been discovered, the function of many proteins and cytokines is known. 
Interleukin-1, specifically interleukin-1β (IL-1β), is proposed as one of the factors 
mediating cross-communication between the maternal endometrium and the 
implanting blastocyst (Simon et al. 1994; Simon et al. 1997). IL-1β also induces 
expression of IGFBP-I, which allows dissociation of filamentous actin during 
decidualization (Kim et al. 1999) and MMP-3, which degrades several 
components of the extracellular matrix and basement membrane thus allowing 
decidualization to ensue (Hemberger 2012). Lastly, insulin-like growth factor 
(IGF) signaling systems allow cell-cell communication between fetal trophoblasts 
and maternal decidual cells by interactions between IGF-II and IGFBP-I, 
(Hamilton et al. 1998) which may act synergistically to enhance trophoblast 
migration. In conclusion, the fate of implantation is likely due to the balance 
between the invasive promoting protease generated by trophoblasts and the 
inhibitors of invasion created by the decidua (Feinberg et al. 1989; Graham and 
Lala 1991; Strickland and Richards 1992; Kliman 1994). 
 
1.2.3 Embryogenesis 
Embryogenesis is the progression of events adhered to by the embryo in 
order to form and develop into a healthy baby. Initially, the TE gives rise to the 
chorion, the precursor of the placenta. The ICM contributes to the embryo proper 
and gives rise to the yolk sac, allantois and amnion. Following implantation, the 
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embryoblast forms a bilaminar embryonic disc called the embryonic epiblast, 
which provides most of the cells contributing to the embryo proper (Hall 1999, 
2000). Afterward, gastrulation occurs, where two germ layers are generated from 
the single layered blastula, the inner ectoderm and outer endoderm. The 
mesoderm, the third and middle germ layer, forms secondly (Hall 1999, 2000). 
Each germ layer differentiates into different organs and tissues in the body. The 
ectoderm becomes the epidermis of the skin and the neural tissue. It also 
differentiates into numerous crucial reproductive organs such as the mammary 
glands, the hypothalamus, both pituitary lobes, the caudal vagina, the vestibule, 
the penis and the clitoris (Gilbert 2000). The endoderm forms the lining of the 
gastrointestinal and respiratory tract as well as their derivatives. Finally, the 
mesoderm differentiates into the urogenital, circulatory and supportive muscular 
system as well as the female and male gonads, the uterus, the cervix, the cranial 
vagina, the epididymis and the accessory glands (Senger 2003; McGeady et al. 
2006). Additionally, a fourth germ layer arises during primary neurulation called 
the neural crest (Hall 1999, 2000). Once all germ layers have been established, 
organogenesis begins. Organogenesis is the process through which individual 
germ layers develop into the internal organs of the body, and is initiated by 
secondary neurulation and the formation of the neural tube. Also, blastema cells 
(cells capable of growing and regenerating into bodily tissues and organs) 
differentiate into the hindgut, blood vessels, somites, trunk neural crest cells, and 
the notochord (Hall 1998; O’Rahilly and Müller 1999). At this point, organ 
development continues and includes formation of the central nervous system, the 
epidermis, cutaneous structures, the skeletal and muscular system, the heart, 
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blood vessels and cells, the respiratory and gastrointestinal tract, sex organs and 
all other systems in the body (Gilbert 2000).  
 
1.2.4 Placentation 
Placentation is the formation and arrangement of the placenta. In the 
mammal, as formerly described, the placenta is derived from the trophoblast cells 
of the TE (Johnson and McConnell 2004). Immediately after implantation, TE 
cells that are not in direct contact with the ICM differentiate into highly polyploid 
trophoblast giant cells that line the entire implantation site (Sutherland 2003; 
Hemberger 2012). These cells, along with a juxtaposed layer of endodermal 
cells, form the parietal yolk sac, (Chazaud et al. 2006) which mediates nutrient, 
gas, and waste exchange between the mother and embryo before the mature 
placenta takes over on embryonic day 9.5-10.5 (Hemberger 2012). Furthermore, 
the parietal trophoblast giant cells protect the embryo through a microbial 
defense system and shield the embryo from immune rejection by the mother 
(Amarante-Paffaro et al. 2004). Contrastingly, the TE cells that are in contact with 
the ICM continue to proliferate, give rise to extra-embryonic ectoderm (ExE) cells, 
and migrate into the ectoplacental cone (EPC) (Hemberger 2012).  At this stage, 
the peripheral cells cease to proliferate. They become larger and less congested 
and differentiate into a secondary population of trophoblast giant cells (Parast et 
al. 2001; Sutherland 2003). This proliferative zone is necessary to provide a 
sufficient number of cells to form the future placenta.  
In the mouse, the placenta forms around mid-gestation into three layers: 
the maternal decidua, the junctional zone and the labyrinth (Hemberger 2012). 
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The functions most attributed to the placenta are nutrient and gas exchange, 
which are accredited to the labyrinth in the mouse, and the chorionic villi in the 
human (Rossant and Cross 2001). This layer is formed by fusion of the allantois 
and the chorion, and branches out at defined initiation sites to establish an 
intricate fetal vascular network. This network ensures that the maternal and fetal 
blood circulation come into very close contact, but never intermingle, ensuring 
continued fetal growth (Hemberger 2012). 
 
1.2.5 Parturition 
Parturition is the step-by-step process of giving birth, and is the last stage 
in fetal development. There are five independent physiological actions that 
constitute parturition: fetal membrane rupture, cervical dilatation, myometrial 
contractility, placental separation and finally uterine involution (Olson et al. 1995). 
These events result in the birth of the baby and the restoration of a regular 
cyclical uterine physiology. The process by which parturition is initiated has been 
extensively investigated. Pregnancy is characterized by long-duration and low-
amplitude contractions in the myometrium, whereas contractions become shorter, 
high amplitude and synchronous throughout the entire muscle during active labor 
(Taylor et al. 1983). Uterine quiescence is a state maintained throughout 
pregnancy, and is controlled by high concentrations of progesterone. When 
progesterone quantities are elevated, the myometrium does not contract when 
stimulated by oxytocin or PGF2α (Challis and Olsen 1988). However, the 
dormancy state is lost during childbirth, and labor initiation is suggestively 
controlled by a reduction in the concentration of circulating progesterone (Csapo 
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1956). Uterine activation and stimulation are considered two separate but parallel 
physiological events (Lye and Challis 1989). To begin, uterine activation is 
considered to be the result of a relative surge of estrogen at term in the face of a 
high progesterone environment (Albrecht and Pepe 1990; Olsen et al. 1995). 
Activation incorporates many modifications in myometrial cells, such as resting 
membrane potential changes, augmented levels of myosin and actin, elevated 
gap junction, oxytocin and prostaglandin (PG) receptor expression and finally an 
increase of post-receptor coupling mechanisms (Olsen et al. 1995). Interestingly, 
PGs have been shown to have a role in uterine activation by stimulating the 
formation of gap junctions in rat myometrium (Garfield et al. 1980). Secondly, 
uterine contractile stimulation is linked to increasing myometrial responsiveness 
to oxytocin in late gestation (Nathanielsz and Honnebier 1992; Hirst et al. 1993). 
Hirst et al. 1991 discovered that the intensity and duration of contractions 
amplified in parallel with growing levels of oxytocin in rhesus monkey plasma. 
While oxytocin is not responsible for the onset and timing of labor, it contributes 
to the expulsive phase of parturition. Moreover, PGs are also essential in 
maintenance of labor, and like oxytocin, their levels rise after labour has started 
and through out its progression. Lastly, hormones initiating, activating and 
stimulating parturition may be coordinated in part by an intrauterine 
communication system composed of steroids, cytokines and PGs (Keirse 1990; 
Olsen et al. 1995). While research is quickly advancing, the process of parturition 
is complex and inadequately understood, requiring additional studies before a 
complete understanding of the mechanisms controlling labor are effectively 
known. 
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1.3 Herbal Medicines and Pregnancy 
Intriguingly, most survey data indicate that women are the predominant 
users of herbal medicines (MacLennan et al. 1996; Eisenberg et al. 1998; Ernst 
and White 2000), and as previously indicated, 9.1% of pregnant women take 
herbal supplements through out their pregnancy (Chin 2001). The most alarming 
fact surrounding these statistics however, is the lack of accessible resources and 
information regarding the safety of consuming herbal supplements during 
pregnancy. While information may be preliminary, herbs have been associated 
with possible health risks through out child bearing (Ernst 2002).  
The definition of a word helps people understand its significance and 
importance. Due to the fact that herbal remedies are characterized as 
“supplements” and are deemed “natural”, consumers often believe that they are 
inherently safe and do not have similar properties to drugs that can have 
biological and clinical effects when ingested. This of course is a false assumption. 
The general population needs to be careful when contemplating herbal remedies 
(Stein 2002). In many countries, including the United States, natural products are 
not rigorously regulated, and people may not necessarily know what they are 
consuming (De Smet et al. 2004). It is clear that these products can have clinical 
effects on the body, however because they are not classified as drugs, they do 
not require approval or rigorous testing by the FDA before they are put on the 
market (Stein 2002). Furthermore, the only way the FDA is empowered to 
remove herbal remedies from the consumer’s reach is if they are proven unsafe 
rather than initially being proven safe by the manufacturer (Goldman 2001). 
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Undeniable characteristics of herbal remedies mark them and their potential 
therapeutic effects as unpredictable, as follows:  
Phytochemical studies have indicated that the concentration of the 
principal compounds present in several herbal supplements on the market, such 
as St. John’s wart, ginko, Echinacea, soy and ginseng, vary dramatically from 
product to product (De Smet et al. 2004). For example, hypericin is a bioactive 
compound found in St. John’s Wart. On the label of different products found at a 
local health food store, it was stated that levels of 0.3% hypericin differed for 
many products and ranged between 180mg and 530mg. Other labels listed 
hypericin but did not include the concentration or amount of active ingredient in 
the product or simply stated that parts of the plant were used but not the specific 
compounds found in them. Finally, while some labels did indicate an awareness 
of certain studies performed on hyperforin, others indicated that no barriers exist 
to selling herbal remedies of uncertain potency and safety (Goldman 2001). 
Unfortunately, there are many limitations to our understanding of all the active 
compounds found in herbal products, and setting a standard for each of them 
individually would be extremely challenging if not near impossible. 
 Chemical analysis is no longer valuable when the ingredients responsible 
for a plant’s activity are unknown and have not been identified. On another note, 
even if these compounds are identified, it is difficult to assess if the crude herb 
would be preferable to ingesting the purified active compound (Goldman 2001). 
While a method of standardization for compounds found in herbal products would 
be indispensable for their quality and safety, any guidelines put into place would 
be futile without complete adherence of future regulations by the manufacturers 
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as well as supervision at the retail level. In a Canadian study conducted by Mills 
et al. 2003, simulated customers visited 33 health food stores one month after 
Health Canada published a warning about the hepatotoxic potential of kava. It 
was found that 67% of these stores were still selling kava. When the Canadian 
ban on kava was made official and 30 stores were revisited two months later, it 
was shown that 57% were still selling the dangerous supplement.  
Many herbal supplements produce undesirable effects in the body such as 
headaches, vaginal spotting, and gastrointestinal discomfort (De Smet et al. 
2004). As previously stated, these products are often believed by the public to be 
safe due to their natural and organic origins (De Smet et al. 2004). Largely due to 
this misconception, half of the herbs taken by patients are not reported to their 
physicians, thus a correlation between consumption of natural health 
supplements and some of the adverse effects experienced are not commonly 
understood (Foster et al. 2000). Furthermore, although no reliable figures about 
underreporting of herbal adverse outcomes are available, it has been suggested 
that less than 1% of undesirable incidences associated with herbal remedies are 
reported to the FDA in the United States (Marcus and Grollman 2002).  This 
implies that most of the information regarding the harmful effects produced by 
these products is not available to the general population, which prevents the 
public from making educated choices when deciding to incorporate herbal 
supplements into their diets. An additional serious factor when considering the 
consumption of herbal supplements is the likely presence of contaminants and 
adulterants such as high levels of pesticides, fumigation agents, pathogens, 
microbial toxins or toxic botanicals (De Smet et al. 2004). Particularly concerning 
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is the presence of toxic levels of heavy metals such as mercury, lead and arsenic 
in several Asian medicines purchased in Asian health food stores in the USA, 
even when taking the suggested dose found on the package (Garvey et al. 2001). 
These adulterants are rarely listed on labels, which make them especially 
dangerous. In a California study of Asian medicines purchased from herbal 
stores, 32% of a 260 product sample contained undeclared pharmaceuticals or 
heavy metals, and 23 had more than one adulterant (Ko 1998). Among the 
contaminants found in some Asian herbal remedies are also synthetic 
pharmaceuticals such as antihistamines, aromatics, steroids and alkaloids 
(Joubert and Mathibe 1989; Gorey et al. 1992; Chen et al. 1993).  
Unknown additives in health products are a cause for concern, and the 
industry clearly states that not all compounds and chemicals present in 
supplements are known or advertised. This indicates that the public must 
approach the ingestion of herbal products with great caution, not only for 
personal knowledge and safety but also due to possible dangerous 
consequences, such as drug interactions. To illustrate, in a group of normal 
volunteers being administered St. John’s wort for 10 days, it was revealed that 
the herbal product reduced absorption of the drug digoxin by an average of 25% 
(Johne et al. 1999). Furthermore, case reports also indicated a significant 
increase in the metabolism of other drugs when ingesting St. John’s wort, 
including cyclosporine (Ruschitzka et al. 2000), warfarin (Yue et al. 2000), and 
oral contraceptives (Ernst 1999). While many people have readily welcomed the 
opportunity to gain access to natural remedies claiming to deliver solutions to 
some of their health concerns, it may not be so simple due to the lack of reliable 
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information provided about these products (Goldman 2001). 
 
1.4 Properties of Ginseng and Ginsenosides 
Ginseng is an herbal supplement with a complex chemical composition. 
Established compounds are extensive and include polysaccharides (PS), 
peptides, polyacetylenic acids, saponins, fatty acids and ginsenosides (Lee 
1992). It is suggested that these different composites differ depending on the 
species, root age, cultivation time and the method of production (Liberti and Der 
Marderosian 1978). Due to production method variation, it is clear that steamed 
ginseng products have greater pharmacological potency than non-steamed 
ginseng as well as differing bioactive components (Yun 2003). For instance, 
using heat (Kim et al. 2000) or sonication (Fuzzati et al. 2000) increases 
ginsenoside recovery and biological activity. Specific ginsenosides and their 
concentrations will also differ when looking at distinctive ginseng products. For 
example, 25 ginseng products purchased from health food stores were tested for 
product-to-product variability in ginsenoside concentration. It was found that 
ginsenoside quantities varied 15-fold (0.288-4.255% by weight) in the powders 
and capsules per 100g of product, and 36-fold (0.361-12.993 g/L) in the liquid 
extracts for 100mL of product (Harkey et al. 2001). Finally, the unique chemical 
structure of each individual ginsenoside along with the different combination of 
compounds found in each specific species are what produce different 
pharmacological and physiological effects in the body (Sievenpiper et al. 2003) 
such as antioxidant, anti-inflammatory and anti-carcinogenesis benefits 
(Wargovich 2001; Kang et al. 2007; Lee et al. 2009;). The ginsenosides are the 
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principal bioactive constituents of interest for understanding ginseng medicinal 
effects. Approximately 40 ginsenoside compounds have been identified from the 
ginseng root and their separation and analysis methods have been extensively 
reviewed (Fuzzati 2004). 
 The most common types of ginseng are American ginseng (Panax 
quinquefolium L.) and Asian ginseng (Panax ginseng C. A. Meyer) (Lü et al. 
2009). North American ginseng (NAG) has a similar ginsenoside profile to Asian 
ginseng. Some marked differences however include a much higher concentration 
of ginsenosides Rb1 and Re in the root of NAG, and little to no Rf (Hu and Kitts 
2001). In addition, Dr. Edmund Lui at the University of Western Ontario has 
determined that the ALC extract derived from NAG possesses twice the total 
concentration of ginsenosides as the AQ extract, specifically 282.5 mg/g versus 
138.7 mg/g. It was also found that the ALC extract has more Rb1 and Re, but a 
lower concentration of Rg1 than the AQ extract. In addition, the major difference 
between both extracts is that the AQ extract is composed of 15% 
polysaccharides, whereas the ALC extract has none. Ginsenosides belong to a 
family of steroids called triterpene saponins and have a four-ring, steroid like 
structure with sugar moieties attached. Sugar moieties include but are not 
restricted to glucose, maltose, fructose and saccharose and are attached to C-3, 
C-6 and C-20 of the chemical structure (Attele et al. 1999). Each one also has at 
least two or three hydroxyl groups and depending on their aglycone are either 
derivatives of the (20S)-protopanaxadiols (PD), (20S)-protopanaxatriols (PT), 
(Tawab et al. 2010) acotillol-type or oleanolic acid groups (Fuzzati 2004).  
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Figure 1.1 Chemical Structures of Main Ginsenosides and their Key 
Degradation Products.  
 Chemical structure and m/z values of main ginsenosides in the 
protopanaxadiol and protopanaxatriol groups, as well as their key degradation 
products. Also, major fragment ions detected in the initial fragmentation step 
(MS2). 
 
 
 
 
 
 
 
 
 
 
 
 
 18
Ginsenoside Structural Diversity 
 
 
 
 
Tawab, M. A., U. Bahr, et al. (2003) Degradation of ginsenosides in humans after oral 
administration. Drug Metabolism and Disposition. 31: 1065-1071 
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1.5 Pharmacokinetics of Ginseng  
  The precise plasma level of ginseng and intact ginsenosides in the human 
body after daily ginseng consumption is undetermined, as well as whether 
absorption of intact ginsenosides by the human gastrointestinal tract is possible 
(Tawab et al. 2003). It is now clear that PDs such as Rb1 are converted to 
compound-K by enzymes from intestinal bacteria (B-D-glucosidase) through step 
wise cleavage of the sugar moieties, (Hasegawa et al. 1996) and PTs such as Re 
and Rg1 are hydrolyzed into ginsenoside Rh1 and Rf1 under mild acidic 
conditions (Han et al. 1982). This results in a small percentage of intact 
ginsenosides being absorbed by the gastrointestinal tract after oral administration 
in humans and animals. While many have attempted to discover these 
ginsenoside levels, results often vary. The individual amount of each identified 
ginsenoside and their metabolites in plasma are not known, however, it was 
found that the maximum concentrations of ginsenosides R1, Rg1, Rd, Re and 
Rb1 in rat plasma after an oral administration of 10 and 300mg/kg of ginseng 
powder were between 1.51 to 6.42 ug/ml on average when samples were taken 
regularly over four days (Li et al. 2007a). Additionally, their absolute 
bioavailability was 9.29%, 6.06%, 2.36%, 7.06% and 1.18% respectively (Li et al. 
2007b). Levels of Rb1 and Rg1 in the plasma have also been determined for 
pregnant female mice on gestational day 18 by Shin et al. 2010. Standard 
solutions were made and 10, 100, 500, 1,000, and 2,000 µg of ginsenoside Rb1 
and Rg1 were dissolved in methanol, filtered and 20ul of each solution was 
analyzed by HPLC. It was found that their concentrations in Korean Red Ginseng 
Extract are 0.61±0.12% and 0.9±0.17% respectively. However in this case, while 
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Rb1, Rg1 and Re were detected after spiking in normal serum, no trace of these 
ginsenosides were found in plasma following treatment with the highest dose of 
2000mg/kg/day after 30 min and 2h. It was suggested that these ginsenosides do 
not reach a detectable blood level by oral treatment due to low absorption in the 
gastrointestinal tract.  
In the human, Cui et al. 1997 demonstrated that ginsenosides are present 
in urine after oral consumption. They demonstrated that 1.2% of a three mg dose 
of orally ingested protopanaxatiol ginsenosides and 0.2% of a seven mg dose of 
orally ingested protopanaxadiols were recovered in the urine over five days. Yet, 
neither the ginsenoside nor its metabolite could be identified, simply the 
aglycone. Ginsenosides Rg1, Rd, Re, Rb2 and Rc are more easily detected in 
urine than in plasma, which may be attributed to the lower limit of detection 
present in urine and indicates that their concentrations in plasma must be 
extremely low. It has been documented that even though low levels of intact 
ginsenosides are found in mouse plasma, that only ginsenoside Rb1 was 
detectable in human blood, and by only one subject (Tawab et al. 2003). This is 
due to the fact that only hydrolyzed and metabolized compounds are able to 
reach the systemic circulation. The only degradation products to reach circulation 
were Rh1 and Rf1 derived from PTs and compound-K originated from PDs 
digested in the intestine (Tawab et al. 2003). With the exception of Rb1, it was 
established that high levels of intact ginsenosides are not able to reach the 
plasma because they are first metabolized. Additionally, while it has been 
discovered that low ginsenoside accumulation and bioavailability are due to 
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decomposition in the stomach, metabolism in the intestine and elimination in the 
liver, it is believed that low membrane permeability is the dominant factor (Han 
and Fang 2006). These results indicate that ginsenoside pharmacokinetics are 
incredibility variable from one study to another and from one species to another. 
Thus pharmacokinetics of ginseng extracts and placental transfer of ginsenosides 
in humans must be investigated further.  
 
1.6 Beneficial Effects of Ginseng and Ginsenosides 
The scientific literature supports that ginsenosides are responsible for 
most of ginseng’s medicinal activities; however non-ginsenoside compounds also 
exert certain pharmacological effects, indicating that the whole root can offer 
therapeutic advantages (Lü et al. 2009). Ginseng is one of the more frequently 
purchased herbs in the US and has been used as an herbal supplement for 
hundreds of years by people wanting to boost energy levels, reduce stress and 
possibly increase lifespan by maintaining a healthy lifestyle (Angelova et al. 
2008). People with certain illnesses also use ginseng. For instance, patients with 
cardiovascular disease and HIV use this herbal remedy in conjunction with their 
treatments. A Canadian survey conducted in 2003 found that 6% of patients with 
cardiac illnesses reported use of ginseng (Wood et al. 2003). Interestingly, 
ginseng is also used by 34% of HIV positive patients on antiretroviral therapy 
making it the 10th most used complementary and alternative medicine (Standish 
et al. 2001). Due to the overall activity and complexity of the herb, its use to 
target benefit to a wide number of the various systems of the body is not 
surprising.  
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1.6.1 Reduction of Blood Glucose and Improvement of Diabetes 
 Diabetes is a major global health problem affecting about 3% of the world 
population (Park et al. 2005). Of this 3% worldwide, over 90% of diabetic patients 
have type two diabetes, which is mostly related to aging, diet and lifestyle. It can 
cause serious health complications and can reduce life expectancy by 8-10 years 
(Astrup and Finer 2000). Fortunately, it has been observed that the root of Panax 
ginseng can be used to improve glucose homeostasis and insulin sensitivity 
(Sonnenborn and Proppert 1990). Genetically obese diabetic mice treated with a 
single 90mg/kg dose of ginseng root extract by intraperitoneal injection had 
significantly lower glucose blood levels (Kimura et al. 1999). Furthermore, when 
type two diabetic patients and non-diabetic patients were administered three g of 
American ginseng root 40 minutes before a test meal, it was demonstrated that 
blood glucose levels were lowered in both patient groups (Vuksan et al. 2000). 
Ginseng therapy for type two diabetic patients has been shown to significantly 
lower blood sugar levels, but it additionally reduces fasting blood glucose and 
body weight, elevates mood and improves psychophysical performance (Park et 
al., 2005). These observations signify that ginseng may not only be beneficial for 
type two diabetic patients, but also more surprisingly for the non-diabetic 
population as a preventative measure against developing diabetes in the future. 
 
1.6.2 Antihypertensive Effects 
High blood pressure (BP) is associated with many life threatening 
diseases and is correlated with an augmented risk of stroke, coronary heart 
disease and end-organ illnesses such as renal failure (Park et al. 2005). 
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Intracellular Ca2+ availability regulates blood vessel smooth muscle tone and is 
strongly influenced by cellular membrane and sarcoplasmic reticulum interaction 
in the muscle. In order to establish the effectiveness of a particular drug on high 
BP, its influence on the smooth muscle can be analyzed (Lee 1980). It was 
discovered that protopanaxadiols (PD) and protopanaxatriols (PT) inhibit Ca2+ 
binding to the cellular membrane, and that PT ginsenosides were approximately 
180% more effective (Lee 1980). Ginseng consumption is thus linked with 
normalizing the BP of hypertensive patients (Yammamoto 1992). Additionally, 
ginsenosides also lower BP in a dose dependent manner in rats administered 
doses of 10-100mg/kg by mediating the release of endothelium-derived nitric 
oxide (NO). NO increases the accumulation of cGMP and in turn relaxes blood 
vessels (Kim et al. 1994).  
Ginseng is also a potent antiplatelet agent (Teng et al. 1989). Endothelial 
cell damage is the first step in the genesis of thrombosis and arteriosclerosis, 
common precursors of cardiovascular disease. Platelet hyperfunction and 
aggregation is associated with an overproduction of Thromboxane A2, which 
occurs in patients with cardiovascular thrombotic disease (Park et al. 2005). 
Panaxynol is the principal compound in ginseng that exhibits antiplatelet effects 
by preventing thromboxane production (Teng et al. 1989). It was also revealed 
that panaxynol inhibits aggregation, and thromboxane release and formation in 
rabbit platelets, whereas ginsenosides Ro, Rg1 and Rg1 blocked release only 
(Kuo et al. 1990). These results certainly suggest that ginseng may have a 
therapeutic role in offsetting or even treating various cardiovascular diseases.  
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1.6.3 Antioxidant Effects  
  Ginseng has demonstrated protective effects in the body attributed to its 
antioxidant activities. It has been reveled that at concentrations between 50-
100ug/ml, ginseng can act as a free radical scavenger or hydrogen donor. 
Phenolic contents and MRP levels (Kang et al. 2007) or ginsenosides have been 
suggested as the active compounds responsible for this observed phenomenon 
(Hu and Kitts 2001). Administration of American ginseng was shown to improve 
antioxidant enzyme activity in rats for enzymes such as superoxide dismutase 
and glutathione peroxidase (Fu and Ji 2003). American ginseng has also been 
proven to have a protective effect against free radical damage on myocardial 
cells induced by xanthine by countering the action of free radicals (Zhong and 
Jiang 1997). Moreover, ginsenoside Re has been revealed to exert antioxidant 
properties in cardiomyocytes (Xie et al. 2006) and neuroprotective influences on 
cellular damages stimulated by amyloid and serum free medium (Ji et al. 2006). 
Additionally, it has been confirmed that ginsenoside Rd can improve astrocyte 
differentiation from neural stem cells (Shi et al. 2005). By increasing antioxidant 
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enzyme levels and acting as a free-radical scavenger, ginseng and ginsenosides 
display protective antioxidant effects on several systems in the body.  
 
1.6.4 The Central Nervous System 
 Ginseng can wield both stimulatory and inhibitory outcomes on the central 
nervous system (Saito et al. 1977), and may have a regulatory role on 
neurotransmission. Ginsenosides Rb1 (Benishin et al. 1992), Rg1 (Yamaguchi et 
al. 1995) and Re (Yamaguchi et al. 1996) have preventative effects against 
scopolamine-induced memory deficits. Central cholinergic systems are involved 
in mediating learning and memory processes (Perry 1986). It was disclosed that 
Rb1 could partially reverse scopolamine-induced amnesia by increasing 
cholinergic activity (Takemoto et al. 1984; Salim et al. 1997) via augmented 
uptake of choline in cholinergic nerve endings (Benishin 1992) and aiding in the 
release of acetylcholine from hippocampal slices (Benishin 1992). These studies 
signify that ginsenosides may improve memory, facilitate learning and effectively 
enhance nerve growth (Takemoto et al. 1984; Salim et al. 1997). On another 
note, ginsenosides can protect neurons from ischemic damage. It was revealed 
that Rb1 rescued hippocampal neurons from fatal ischemic damage (Lim et al. 
1997) and was able to delay neuronal death from transient forebrain ischemia 
(Wen et al. 1996). Finally, ginseng extract is also associated in nerve 
transmission modulation by decreasing neurotransmitter availability. It was 
demonstrated that ginseng can impede uptake of GABA, glutamate, dopamine, 
noradrenalin and serotonin in rat brain synaptosomes (Tsang et al. 1985) and 
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that individual ginsenosides compete with agonists for binding to receptors 
GABAa and GABAb (Kimura et al. 1994). 
 
1.6.5 Anticancer Activities  
While advances in cancer therapies such as radiotherapy, chemotherapy and 
surgical removal are steadily improving treatment and cancer survival rates, 
cancer patients are increasingly turning to natural products for assistance in 
treating their disease, which has stimulated research investigating the chemo-
preventive effects of natural compounds (Park et al. 2005). Ginseng is a very 
effective anti-carcinogenic agent in various different ways. To begin, ginsenoside 
Rh2 inhibits the growth and colony forming ability of Morris hepatoma cells, thus 
transforming the cells characteristics back to those resembling normal liver cells 
both functionally and morphologically (Odashima et al. 1989). Rh2 and Rg3 also 
prevent prostate cancer cell proliferation (Kim et al. 2004). Specific ginsenosides 
also have anti-metastatic effects. Most cancer patients do not succumb to 
primary tumors but to metastases, which are tumor colonies that detach 
themselves and travel to distant regions of the body (Friedberg 1986). Rg3 was 
reported to restrict lung metastasis of tumor cells by preventing invasion and 
adhesion of these cells, as well as having anti-angiogenic properties (Mochizuki 
et al. 1995). Rb2 can inhibit invasion to the basement membrane by suppressing 
MMP-2 in some endometrial cancers and has been used as a medication to 
reduce secondary spreading of uterine endometrial cancers (Fujimoto et al. 
2001). As demonstrated, ginseng has been thoroughly investigated and its 
preventative effects against carcinogenesis are extensive. 
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Administration of Korean red ginseng greatly reduced the incidence and 
proliferation of tumors induced by 7,12-dimethylbenz(a)anthracene (DMBA), 
urethane and aflatoxin B1 (Yun et al. 1983). Furthermore, Korean ginseng was 
characterized as a non-organ specific agent with protective effects against cancer 
mostly due to ginsenosides Rg3, Rg5 and Rh2 (Yun 2003). It also suppressed 
liver (Wu et al. 2001) and colon carcinogenesis through inhibition of cell 
proliferation (Fukushima et al. 2001). On another note, American ginseng plays a 
protective role against breast cancer (Duda et al. 2001) and is often taken along 
with breast cancer therapies due to their synergistic capabilities of suppressing 
breast cancer cell growth (Duda et al. 1999). Finally, orally administered 
ginsenoside Rh2 is associated with tumor growth retardation in human ovarian 
cancer cells (HRA) (Tode et al. 1993) and apoptosis induction in tumors. Rh2 
increases natural killer activity in spleen cells of tumor-bearing nude mice 
(Nakata et al. 1998). Thus apoptosis, inhibition of cell growth and invasion, and 
tumor proliferation reduction seem to be some of ginseng’s many anti-
carcinogenic mechanisms.   
 
1.7 Effects of Ginseng on the Reproductive System 
 Research to date has indicated that ginseng’s effects on the body can be 
either beneficial or harmful, and its influences on the reproductive system are no 
exception. For example, Ginsenoside Rh2 action is associated with tumor growth 
retardation and apoptosis induction in ovarian cancer cells (Tode et al. 1993). 
Also, Ginseng may protect mouse embryos from oxidative stress via activation of 
embryonic antioxidant enzyme defense systems (Lee et al. 2009). In regards to 
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fertility, ginsenoside Re significantly enhances both fertile and infertile sperm 
motility in a concentration dependent manner (Zhang et al. 2006). Furthermore, 
Lee et al. 2008 demonstrated that treatment of early rat embryos with individual 
ginsenosides caused either no change in their morphological score, or improved 
them when compared to those cultured in a normal environment. Conflictingly, it 
was determined that similar treatment with individual ginsenosides actually 
lowered morphological scores for in vitro treated rat and mouse embryos (Chan 
et al. 2003, 2004; Liu et al. 2005a, 2005b, 2006), which could be potentially 
hazardous for embryonic and fetal development. On another note, very recent in 
vivo studies have demonstrated that when administering Korean Red Ginseng 
extract to females for two weeks before mating and through out gestation, that 
maternal weight, feeding, embryonic implantation and fetal growth were not 
significantly affected (Shin et al. 2010). Thus the potential for ginseng to affect 
the reproductive system is significant and must to be considered when deciding 
to incorporate ginseng as part of a healthy lifestyle. Additionally, with more 
people taking herbal supplements (Eisenberg et al. 1998) and the majority being 
women (MacLennan et al. 1996; Eisenberg et al. 1998; Ernst and White 2000), 
understanding ginseng’s effect on fertility, pregnancy and post-partum 
development is of utmost importance for future reproductive health. To date, no 
studies have investigated the effects of North American Ginseng extracts on 
reproductive function, and my study is focused on providing essential data related 
to the safety of ginseng consumption on early development in vitro and 
pregnancy and postpartum development in the mouse.  
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1.8 Hypothesis and Objectives 
The principal hypothesis of this study is that aqueous and alcoholic 
ginseng treatment will promote preimplantation development, pregnancy and 
post-partum development in the mouse.  
This study has addressed the following objectives to test my principal 
hypothesis:  
1) Investigate the concentration response effect of aqueous and alcohol 
ginseng extracts, specific ginsenosides and polysaccharides on mouse 
preimplantation development in vitro.  
2) Investigate the combinatorial effect of ginsenosides Rb1, Rg1 and Re on 
mouse preimplantation development in vitro.  
3) Investigate the safety of consuming both ginseng extracts on fertility, 
pregnancy and post-partum development in the mouse.  
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Methods and Materials 
 
2.1 Objective One 
Investigate the concentration response effect of aqueous and alcoholic ginseng 
extracts, specific ginsenosides and polysaccharides on mouse preimplantation 
development.  
 
Chemicals 
KSOMaa (potassium simplex optimized medium with amino acids) was used for 
embryo culture medium (Chemicon, Temecula, CA, USA). The Ontario Ginseng 
Growers Association provided four-year-old North American ginseng roots, which 
were shipped to Naturex (USA) for extraction. To begin, four kg of the ginseng 
root was ground to ½ and ¼ inch, and used to produce the AQ and ALC extract. 
The ground roots were soaked three times for five hours in 16 L of either water or 
ethanol/water (75/25, v/v) solution at 40°C. The solution was then extracted and 
filtered, and the excess solvent was removed by rotary evaporator under vacuum 
at 45°C. The three pools were combined and concentrated until the total dry 
solids were around 60%. Finally these concentrates were lyophilized at -50°C 
(Labconco, USA) under reduced pressure to produce either the AQ or ALC 
extracts. Yield of the powder extracts from the concentrates was about 66%. 
Final yields for the aqueous and alcoholic extract (mean ± standard deviation of 
% extractive) were 41.74 ± 4.92 and 35.30 ± 5.01 respectively. The lyophilized 
ALC, AQ ginseng extracts and polysaccharide fraction were obtained from Dr. 
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Edmund Lui and prepared in accordance with Azike et al., 2011. Ginsenosides 
Rb1, Rg1 and Re were purchased from Sigma (St Louis Mo. USA).  
 
Animals  
All animal care and handling procedures were conducted as approved by the 
University of Western Ontario, Animal Care and Veterinary Science (ACVS), 
standard operating procedures, that conform to guidelines produced by the 
Canadian Council for Animal Care (CCAC). Six-eight week old female MFI mice 
were purchased from Harlan Sciences, (Indiana, USA) and CD1 mice were 
purchased from Charles River (Canada). Each female was injected with 0.1 ml 
PMSG, then 0.1 ml hCG 48 h later and placed with CD1 males for mating. 
Pregnancy was confirmed the following morning by the presence of a vaginal 
plug which was considered gestational day one. On gestational day two, the mice 
were euthanized employing CO2 asphyxiation, followed by cervical dislocation as 
outlined in Western University ACVS standard operating procedures. Mice were 
then dissected and oviducts were removed and flushed with M2 flushing medium 
(Sigma, St Louis, MO, USA) to collect two-cell stage zygotes for experimental 
purposes. 
 
Experimental Groups 
Alcohol and Aqueous Ginseng Extracts 
The two-cell embryos were washed three consecutive times in KSOMaa. Then 
0.01 g of the alcoholic and aqueous ginseng extracts were individually mixed with 
1 mL KSOMaa to prepare two individual 10 000 µg/ml stock solutions. These 
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stock solutions were then used to make five different concentrations of each 
extract: 0 (control), 10, 50, 250 and 1000 µg/ml. In all groups, 20 embryos were 
cultured in 20 µl drops under oil. All treatment groups were then put into culture at 
37°C under a 5% O2, 5% CO2 and 90% N2 atmosphere for 48 h.  
 
Ginsenoside Rb1, Rg1 and, Re 
Five groups were established for Rb1, Rg1, and Re. Ginsenoside concentrations 
were calculated to equal the actual individual concentrations in the aqueous and 
alcoholic extracts. 1 mg of ginsenoside Rb1, Rg1 and Re were individually mixed 
with 1 mL KSOMaa to prepare three -1000 µg/ml stock solutions. The stock 
solutions were then used to make five different concentrations for each individual 
ginsenoside equal to the AQ extract: Rb1 was 66.2, 16.6, 3.3, 0.7 and 0 µg/ml; 
Rg1 was 13.1, 2.6, 0.66, 0.15 and 0 µg/ml; Re was 55.9, 14.0, 2.8, 0.6 and 0 
µg/ml, and five different concentrations for each individual ginsenoside equal to 
the alcoholic extract: Rb1 was 164.5, 41.1, 8.2, 1.6 and 0 µg/ml; Rg1 was 2.66, 
0.66, 0.15, 0.03 and 0 µg/ml; Re was 89.6, 22.4, 4.5, 0.9 and 0 µg/ml. In all 
groups, 20 embryos were cultured in 20 µl drops under oil. All treatment groups 
were then put into culture at 37°C under a 5% O2, 5% CO2 and 90% N2 
atmosphere for 48 h. 
 
Polysaccharide Fraction 
For all experiments conducted with the polysaccharide fraction, CD1 females 
were used. Five different groups were established for treatment with the 
polysaccharide fraction (PSF). 15% of the aqueous extract is composed of PS, 
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thus this percentage was used in order to calculate the five concentrations used. 
The highest concentration of the aqueous extract is 1000 µg/ml, which translates 
into 150 µg/ml PS present in this solution at the highest concentration. 0.01 g of 
the PSF was mixed with 1 mL KSOMaa to prepare a 10 000 µg/ml stock solution. 
The stock solution was then used to make the following concentrations: 150, 
37.5, 7.5, 1.5 and 0 µg/ml. In all groups, 20 embryos were cultured in 20 µl drops 
under oil. All treatment groups were then put into culture at 37°C under a 5% O2, 
5% CO2 and 90% N2 atmosphere for 48h. 
 
Morphological Assessment 
Embryo development was assessed after 48 h of treatment. After treatment and 
culture, the cell number of each embryo was determined and it was categorized 
into 2, 4 or 8 cells, 8-cell compacted, morula or blastocyst groups. Micrographs of 
the five groups were taken and the cultures were returned to the incubator.  
 
Recovery from Treatment 
After the morphological assessment following 48 h of treatment, embryos were 
washed three consecutive times in KSOMaa and returned to culture in clean 
drops of culture media for another 72 h in order to determine if recovery from 
treatment effects was possible. After 24 and 72 h, embryos were once again 
categorized into their specific developmental stages and micrographs were taken. 
Progression on to the blastocyst stage was considered to represent full recovery 
from treatment. 
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Statistical Analysis 
All statistical analyses were done with GraphPad Prism version 4.0c software. 
Each experiment was repeated a minimum of three times using embryos 
collected from replicate groups of mice. Data were presented as the mean ± 
standard deviation (SD) for each treatment and each experiment. Two-way RM 
ANOVA evaluated data sets with multiple comparisons. P < 0.05 was considered 
to be statistically significant.  
 
2.2 Objective Two 
To investigate the combinatorial effect of ginsenosides Rb1, Rg1 and Re on 
mouse preimplantation development in vitro.  
 
Chemicals 
KSOMaa (potassium simplex optimized medium with amino acids) was used for 
embryo culture medium (Chemicon, Temecula, CA, USA). Ginsenosides Rb1, 
Rg1 and Re were purchased from Sigma (St Louis Mo. USA). 
 
Animals 
Female CD1 mice (six-eight weeks old) were purchased from Charles River 
(Canada). The experimental design used in objective one was also employed for 
the combinatorial ginsenoside experiments.  
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Experimental Groups 
The two-cell embryos were washed three consecutive times in KSOMaa. 
Ginsenoside concentrations were calculated to equal the actual individual 
concentrations of Rb1, Rg1 and Re found in the alcoholic extract. 1 mg of purified 
ginsenoside Rb1, Rg1 and Re were individually mixed with 1 mL KSOMaa to 
prepare three -1000 µg/ml stock solutions. The stock solutions were then used to 
prepare a solution for each individual ginsenoside equal to three times the 
concentration found in 1000 µg/ml of the alcoholic extract: Rb1 was 493.5 µg/ml; 
Rg1 was 7.98 µg/ml; Re was 269.7 0 µg/ml. 0.5 mL of each solution was 
combined to give a combinatorial mixture of Rb1, Rg1 and Re equal to 257.1 
µg/ml, which was then diluted to provide the five treatment concentrations of 
257.1, 64.3, 12.9, 2.6 and 0 µg/ml. In all groups, 20 embryos were cultured in 20 
µl drops under oil. All treatment groups were then put into culture at 37°C under a 
5% O2, 5% CO2 and 90% N2 atmosphere for 48 h. 
 
The morphological assessment, embryonic recovery and statistical analyses 
used in objective one were repeated for the combinatorial ginsenoside 
experiments. 
 
2.3 Objective Three 
To investigate the safety of consuming both ginseng extracts on pregnancy and 
post-partum development in the mouse. 
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Chemicals 
The AQ and ALC ginseng extracts used were provided by Dr. Edmund Lui’s lab        
and prepared according to Azike et al. 2011.  
 
Animals  
Female MFI mice (six-eight weeks old) were purchased from Harlan Sciences 
(Indiana, USA). Females receiving sham, AQ or ALC treatments were gavaged 
(using standard operating procedures as outlined by Western University’s ACVS) 
once per day at 9:00 am for 14 days prior to mating, throughout mating and 
during gestation. After 14 days of treatment, females were mated with CD1 
males. Pregnancy was confirmed by the presence of a vaginal plug where 
females were then separated from males and placed into individual cages. If 
pregnancy was not confirmed within five days, females were asphyxiated with 
CO2, followed by cervical dislocation as outlined above. 
 
Gavaging 
Using ACVS standard operating procedures, mice were gavaged with a straight 
stainless steel animal feeding needle (24G x 1 inch) attached to a 1 mL syringe. 
The mouse was lifted and restrained by grasping the loose skin along the nape of 
the neck and back with the thumb and forefinger. In order to determine how far to 
insert the needle, the distance from the oral cavity and the end of the xyphoid 
process was estimated with the feeding needle on the outside of the animal. The 
needle was then inserted into the right lateral side of the oral cavity and gently 
inserted into the back of the oral cavity. Gravity alone was used to move the 
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needle down the esophagus; the mouse then swallowed the needle. The fluid 
was then injected slowly, and the needle was gently removed. The solution 
volume administered was calculated in order to assure that no more than 2 
mL/100 g body weight was gavaged.  
 
Experimental Groups 
In order to prepare the ginseng solutions, 1 mL of distilled water was mixed with 
10 mg of the AQ ginseng extract. The same process was followed for the ALC 
ginseng extract. When administering a dose of 50 mg/kg, the gavaged volume 
was calculated according to individual mouse weights: [0.05 x (weight of mouse) / 
10]. When administering a dose of 500 mg/kg, the solutions were prepared 10 
times more concentrated (100 mg of each extract was used with 1mL distilled 
water). Each experiment consisted of four treatment groups: control-not gavaged, 
sham-gavaged water, gavaged aqueous extract and gavaged alcoholic extract. 
Two principal experiments were conducted, females gavaged 50mg/kg for 14 
days prior to mating and throughout gestation, and females gavaged 500 mg/kg 
for 14 days prior to mating and throughout gestation. N values were 3-6 pregnant 
mice per treatment group per experiment. 
 
Morphological Assessment 
Once litters were born, day of birth, litter size, and gestation period were 
determined for each group in each experiment. Pups were also individually 
weighed every four days until weaning on post-partum day 20. When pups were 
weaned, the sex of the mice was determined.  
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Statistical Analysis 
All statistical analyses were done with GraphPad Prism version 4.0c software. 
Data were presented as the mean ± standard deviation (SD). For litter size, 
gestation period and pup sex, statistical analyses were conducted with an 
unpaired t test and the n value was 3-6. For pup weight, two-way RM ANOVA 
evaluated data sets with multiple comparisons and n values ranged between 201-
247. P < 0.05 was considered to be statistically significant. 
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Results 
 
3.1  Concentration Response Effects of North American Ginseng Extracts and 
their Individual Active Compounds on Mouse Preimplantation 
Development in Vitro.  
3.1.1 The Effect of Aqueous and Alcoholic Ginseng Extract Treatment on 
Preimplantation Development.  
The effect of North American AQ and ALC ginseng extracts on 
preimplantation development in vitro was evaluated by collecting two-cell 
embryos from superovulated and inseminated MF1 females, and placing 
embryos into culture for 48 hours in 0 (control), 10, 50, 250 and 1000 µg/ml of 
both extracts. AQ ginseng extract treatment resulted in a concentration 
responsive inhibition of development (Figure 3.1A). As the concentration of 
ginseng increased, the numbers of embryos developing to the morula and 
blastocyst stages were significantly reduced (p<0.05) with development 
increasingly blocking at the two-cell and four-cell stages (figure 3.1A and 3.2A, C, 
E, G, I). With the highest concentration of 1000 µg/ml, only 1.5% of embryos 
developed to the morula stage, whereas 71.7% and 24.1% of control embryos 
progressed to the morula and blastocyst stage consecutively after 48 hours of 
culture. Treatment with the ALC extract presented a similar outcome with lower 
concentrations of 10, 50 and 250 µg/ml, significantly (p<0.05) increasing the 
numbers of embryos blocked in development at the two-cell stage. Interestingly, 
treatment with 1000 µg/ml resulted in no significant impairment of embryo 
development when compared to the control (figure 3.1B and 3. A, D, F, H, J).  
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Figure 3.1 Development of two-cell Mouse Embryos after 48 h Treatment 
with Aqueous and Alcoholic Ginseng Extracts. Two-cell embryos were 
flushed from the oviduct and placed into culture with the AQ (A) and ALC (B) 
ginseng extract for 48 hours. Treatment groups for both extracts consisted of a 
KSOMaa control (0 µg/ml), 10, 50, 250 and 1000 µg/ml and were put into culture 
at 37°C under a 5% O2, 5% CO2 and 90% N2.  Embryonic development was 
evaluated after 48 hours and embryos were categorized as being 2-cell, 4-cell, 8-
cell, 8-cell compacted, morula or blastocysts. Variations in embryo development 
between treatment groups are presented as the mean ± SD, representative of 
three independent replicates. Significant differences are represented by different 
superscripts (P≤0.05).  
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B 48 h treatment with alcoholic extract 
A 48 h treatment with aqueous extract 
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Figure 3.2 Morphology of Embryos Following Treatment with Five 
different Concentrations of Aqueous and Alcoholic Ginseng Extract for 48 
h. Comparative morphology of representative groups of two-cell embryos after 
treatment with 0 µg/ml (A, B), 10 µg/ml (C, D), 50 µg/ml (E, F), 250 µg/ml (G, H) 
and 1000 µg/ml (I, J) of AQ ginseng extract (A, C, E, G, I) and ALC ginseng 
extract (B, D, F, H, J) for 48 hours. Scale bars represent 100 µm.  
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Following treatment with AQ and ALC ginseng extracts for 48 hours, 
embryos were washed three consecutive times in fresh KSOMaa and returned to 
culture in clean drops of culture medium for an additional 72 hours to determine 
whether ginseng treatment effects were permanent or reversible. Measuring 
progression to the blastocyst stage between control and treatment groups 
assessed recovery from treatment. Embryos treated with 10 µg/ml of the AQ 
extract displayed the strongest recovery from treatment as blastocyst formation 
jumped from 24.1% at 0 h recovery time to 93.8% blastocysts after 72 h of 
recovery time. All other AQ treatment groups displayed a significant (p<0.05) 
decline in embryo development to the blastocyst stage when compared with the 
control, indicative of extremely low recovery potential (Figure 3.3A and 3.4A, B, 
E, F, I, J, M, N, Q, R). In contrast, embryos treated with 10, 50 and 1000 µg/ml of 
the ALC extract were able to fully recover from treatment by displaying no 
significant difference in blastocyst formation between the control and ALC treated 
embryos after a 72 hour recovery period. Interestingly, the developmental 
blockade resulting from treatment with 250 µg/ml ALC extract was only marginally 
reversed with 29.4% of treated embryos developing to the blastocyst stage, as 
opposed to 97.1% for control after 72 h of recovery time (Figure 3.3B and 3.4C, 
D, G, H, K, L, O, P, S, T). The difference in blastocyst formation between these 
two groups was significantly different (p<0.05). All data shown in Figures 3.1 and 
3.3 are presented as the mean ± SD, representative of three independent 
replicates.  
Thus both ginseng extracts negatively affect development to the blastocyst 
stage in vitro. The effects of AQ and ALC treatments on development were only 
 45
reversible following low concentration treatments ie 10 ug/ml for AQ extract and 
10 and 50 ug/ml for ALC. Interestingly, treatment with 1000 ug/ml ALC did not 
negatively affect development to the blastocyst stage.  
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Figure 3.3 Percentage of Mouse Embryos that Recovered from Ginseng 
Treatment. Embryos treated for 48 h with AQ (A) and ALC (B) ginseng extracts 
were washed three consecutive times in KSOMaa and returned to culture in 
clean drops of culture media for 72 h. Progression to the blastocyst stage was 
considered to represent full recovery from treatment. Differences in embryo 
development to the blastocyst stage between treatment groups are presented as 
the mean ± SD, representative of three independent replicates. Significant 
differences are represented by different superscripts (P≤0.05).  
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Figure 3.4 Morphology of Mouse Embryos Following Recovery from 
Treatment with Aqueous and Alcoholic Ginseng Extracts. Comparative 
morphology of representative groups of embryos following wash out and recovery 
from ginseng treatment with 0 µg/ml (A, B, C, D), 10 µg/ml (E, F, G, H), 50 µg/ml 
(I, J, K , L), 250 µg/ml (M, N, O, P) and 1000 µg/ml (Q, R, S, T) of aqueous 
ginseng extract (A, B, E, F, I, J, M, N, Q, R) and alcoholic ginseng extract (C, D, 
G, H, K, L, O, P, S, T) for 24 (A, E, I, M, Q; C, G, K, O, S) and 72 hours (B, F, J, 
N, R; D, H, L, P, T). Scale bars represent 100 µm. 
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3.1.2 The Effect of Treatment with 2000 µg/ml of Aqueous Ginseng Extract 
on Preimplantation Development 
Since the AQ ginseng extract has half the ginsenoside concentration as 
the ALC extract, specifically 138.7 mg/g versus 282.5 mg/g, I next investigated 
whether doubling the concentration of the 1000 µg/ml of AQ extract to 2000 ug/ml 
would replicate the outcomes observed with 1000 µg/ml of ALC ginseng extract. 
two-cell embryos from MF1 females were cultured for 48 hours in 0 (control) and 
2000 µg/ml of AQ extract. In contrast to my observations with using 1000 ug/ml 
ALC treatment (above), none of the embryos treated with 2000 µg/ml developed 
to the morula or blastocyst stages, and all were halted at the two-cell and four-
cell stages (Figure 3.5A). Furthermore, significant (p <0.05) differences in 
blastocyst formation were observed between control and treated embryos once 
the AQ extract treatment was washed out and the cleaned embryos returned to 
culture for 72 h (Figure 3.5B). All data in Figure 3.5 are presented as the mean ± 
SD, representative of three independent replicates. Thus these outcomes 
suggest that the differences in treatment effects between high concentrations of 
AQ and ALC on development to the blastocyst stage are unlikely to be due to 
differences in ginsenoside concentrations between the two extracts. 
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Figure 3.5 Development and Recovery of Two-cell Mouse Embryos Treated 
with 2000 µg/ml of Aqueous Ginseng Extract. Two-cell embryos were flushed 
from the oviduct and placed into culture with aqueous ginseng extract. Treatment 
groups consisted of a KSOMaa control (0 µg/ml) and 2000 µg/ml of the AQ 
extract, and were cultured at 37°C under a 5% O2, 5% CO2 and 90% N2 
atmosphere for 48 h (A). Embryos were then washed three consecutive times in 
KSOMaa and returned to culture in clean drops of culture media for 72 h (B). 
Embryos were categorized as being 2-cell, 4-cell, 8-cell, 8-cell compacted, 
morula or blastocyst after all time points. Progression on to the blastocyst stage 
was considered to represent full recovery from treatment. Differences in embryo 
development to differing embryonic stages or blastocyst formation between 
treatment groups are presented as the mean ± SD, representative of three 
independent replicates. Significant differences are represented by different 
superscripts (P≤0.05).  
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3.1.3 The Effect of Individual Ginsenoside Rb1 Treatment on 
Preimplantation Development.  
My next experiments focused on attempting to define the primary 
constituents of the ginseng extracts that were impeding preimplantation 
development in vitro. I began this process by investigating the concentration 
response effects of increasing individual ginsenosides Rb1, Rg1 and Re 
concentrations on preimplantation development in vitro and concluded these 
experiments by investigating the effects of the polysaccharide fraction on early 
development. 
First, the effect of ginsenoside Rb1 on preimplantation development in 
vitro was evaluated. Two-cell embryos from MF1 females were cultured for 48 h 
with concentrations of ginsenoside Rb1 equal to those found in the aqueous 
extract (Figure 3.6A, B) and alcoholic extract (figure 3.6C, D). AQ level treatment 
groups consisted of 0, 0.7, 3.3, 16.6 and 66.2 µg/ml of Rb1. In contrast to the 
treatment outcomes with the AQ extracts, treatment with Rb1 alone did not 
significantly block embryo development at the two-cell or four-cell stages. 
However, there was a significant difference (p<0.05) between the control and 
treatment with 16.6 µg/ml Rb1, with the treated group displaying a higher 
percentage of morula. This was accompanied by the observation that no embryos 
in the treated groups developed to the blastocyst stage after 48 h treatment, 
while the control group displayed a 10% blastocyst formation frequency (Figure 
3.6A and 3.7A-E). Experimentation using ALC Rb1 treatment levels (0, 1.6, 8.2, 
41.1 and 164.5 µg/ml) resulted in a significant variation between the control and 
treatment with 8.2 µg/ml of ginsenoside Rb1 (Figure 3.6C).  84.1% of embryos in 
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the control group compared to only 65.6% of embryos treated with 8.2 µg/ml 
progressed to the morula stage. No other significant differences in embryo 
development were observed between the treatment groups (Figure 3.6C and 
3.7F-J).  
Embryos treated for 48 h with ginsenoside Rb1 were washed out in 
KSOMaa and returned to culture in clean drops of culture media for 72 h. 
Progression to the blastocyst stage was considered to represent full recovery 
from treatment. For both Rb1 experiments (Figure 3.6B and 3.8A-J; Figure 3.6D 
and 3.8K-T), while blastocyst formation was low at the 0 h mark, embryos in all 
treatment groups were able to recover from treatment and no significant 
differences in development were observed between any treatment groups after 
72 h in culture. All data shown in figure 3.6 is presented as the mean ± SD, 
representative of three independent replicates. 
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Figure 3.6 Development and Recovery of Mouse Embryos Following 
Treatment with Ginsenoside Rb1. Two-cell embryos were flushed from the 
oviduct and placed into culture for 48 h with concentrations of ginsenoside Rb 
equal to those found in the aqueous (A) and alcoholic (C) extracts. Treatment 
groups consisted of: 0, 0.7, 3.3, 16.6 and 66.2 µg/ml (A, B); 0, 1.6, 8.2, 41.1 and 
164.5 µg/ml (C, D). Embryos were then washed three consecutive times in 
KSOMaa and returned to culture in clean drops of culture media for 72 h (B, D). 
Differences in embryo development to differing embryonic stages or blastocyst 
formation between treatment groups are presented as the mean ± SD, 
representative of three independent replicates. Significant differences are 
represented by different superscripts (P≤0.05). 
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Figure 3.7 Morphology of Mouse Embryos Following Rb1 Treatment. 
Comparative morphology of representative groups of embryos after 48 h 
treatment with concentrations of Rb1 equal to those found in the aqueous (A-E) 
and alcoholic (F-J) ginseng extracts.  Treatment groups consisted of: 0 (A), 0.7 
(B), 3.3 (C), 16.6 (D) and 66.2 µg/ml (E); 0 (F), 1.6 (G), 8.2 (H), 41.1 (I) and 
164.5 µg/ml (J). Scale bars represent 100 µm.  
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Figure 3.8 Morphology of Mouse Embryos Following Recovery from Rb1 
Treatment. Comparative morphology of representative groups of embryos 
following wash out and recovery from treatment with 0 µg/ml (A, B and K, L), 0.7 
µg/ml (C, D), 3.3 µg/ml (E, F), 16.6 µg/ml (G, H), 66.2 µg/ml (I, J), 1.6 µg/ml (M, 
N), 8.2 µg/ml (O, P), 41.1 µg/ml (Q, R) and 164.5 µg/ml (S, T) of ginsenoside Rb1 
for 24 (A-J) and 72 hours (K-T). Scale bars represent 100 µm. 
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3.1.4 The Effect of Individual Ginsenoside Rg1 Treatment on 
Preimplantation Development. 
Two-cell embryos from MF1 females were cultured for 48 h with 
concentrations of ginsenoside Rg1 equal to those found in the aqueous extract 
(Figure 3.9A, B) and alcoholic extract (Figure 3.9C, D). AQ levels consisted of 0, 
0.13, 0.66, 2.66 and 13.1 µg/ml. Treatment with Rg1 at AQ levels for 48 h 
resulted in no significant differences (p< 0.05) in embryonic development 
between any of the treatment groups (Figure 3.9A and 3.10A-E).  ALC Rg1 
treatment group levels included 0, 0.03, 0.15, 0.66 and 2.66 µg/ml. The most 
notable difference in developmental outcomes occurred between the control 
group, where 90.5% of embryos progressed to the morula stage whereas in the 
lowest concentration treatment of 0.03 µg/ml, only 71% of the embryos treated 
with Rg1 progressed to the morula stage. In addition, development to the morula 
stage varied significantly (p<0.05) between treatment with concentrations of 0.03, 
0.66 and 2.66 µg/ml as well as 0.66 and 2.66 µg/ml of ginsenoside Rg1 (Figure 
3.9C and 3.10F-J).  
Embryos treated for 48 h with ginsenoside Rg1 were then washed three 
consecutive times in KSOMaa and returned to culture in clean drops of culture 
media for 72 h. No significant differences in blastocyst development were 
observed between controls, and any of the AQ Rg1 treatment groups (Figure 
3.9B and Figure 3.11A-J). In contrast, within the ALC Rg1 treatment groups, 
blastocyst formation was delayed for the 0.03 and 0.15 µg/ml Rg1 treatments in 
comparison to the control at the 24 h time point. However, after 72 h in culture, 
no significant differences in blastocyst development between groups were 
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observed (figure 3.9D and 3.11K-T). All data shown in Figure 3.9 is presented as 
the mean ± SD, representative of three independent replicates. 
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Figure 3.9 Development and Recovery of Mouse Embryos Following 
Treatment with Ginsenoside Rg1. Two-cell embryos were flushed from the 
oviduct and placed into culture for 48 h with concentrations of ginsenoside Rg1 
equal to those found in the aqueous (A) and alcoholic (C) extracts. Treatment 
groups consisted of: 0, 0.13, 0.66, 2.66 and 13.1 µg/ml (A, B); 0, 0.03, 0.15, 0.66 
and 2.6 µg/ml (C, D). Embryos were then washed three consecutive times in 
KSOMaa and returned to culture in clean drops of culture media for 72 h (B, D). 
Embryos were categorized as being 2-cell, 4-cell, 8-cell, 8-cell compacted, 
morula or blastocyst after all time points. Progression on to the blastocyst stage 
was considered to represent full recovery from treatment. Differences in embryo 
development to differing embryonic stages or blastocyst formation between 
treatment groups are presented as the mean ± SD, representative of three 
independent replicates. Significant differences are represented by different 
superscripts (P≤0.05). 
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Figure 3.10 Morphology of Mouse Embryos Following Rg1 Treatment. 
Comparative morphology of representative groups of embryos after 48 h 
treatment with concentrations of Rg1 equal to those found in the aqueous (A-E) 
and alcoholic (F-J) ginseng extracts.  Treatment groups consisted of: 0 (A), 0.13 
(B), 0.66 (C), 2.66 (D) and 13.1 µg/ml (E); 0 (F), 0.03 (G), 0.15 (H), 0.66 (I) and 
2.6 µg/ml (J). Scale bars represent 100 µm.  
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Figure 3.11 Morphology of Mouse Embryos Following Recovery from Rg1 
Treatment. Comparative morphology of representative groups of embryos once 
recovered from treatment with 0 µg/ml (A, B and K, L), 0.13 µg/ml (C, D), 0.66 
µg/ml (E, F), 2.66 µg/ml (G, H), 13.1 µg/ml (I, J), 0.03 µg/ml (M, N), 0.15 µg/ml 
(O, P), 0.66 µg/ml (Q, R) and 2.6 µg/ml (S, T) of ginsenoside Rg1 for 24 (A-J) 
and 72 hours (K-T). Scale bars represent 100 µm. 
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3.1.5 The Effect of Individual Ginsenoside Re Treatment on 
Preimplantation Development. 
 Two-cell embryos from MF1 females were cultured for 48 h with 
concentrations of ginsenoside Re equal to those found in the aqueous extract 
(Figure 3.12A, B) and the alcoholic extract (Figure 3.12C, D). Treatment groups 
consisted of: 0, 0.6, 2.8, 14.0 and 55.9 µg/ml for AQ Re levels and 0, 0.9, 4.5, 
22.4 and 89.9 µg/ml for ALC Re levels. For all treatments, including 72 h 
recovery, with both AQ Re and ALC Re concentrations, no significant variations 
in embryo development between the control and treatment groups were observed 
(Figure 3.12A,C and 3.13; Figure 3.12B and 3.14A-J; Figure 3.12D and 3.14K-T).   
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Figure 3.12 Development and Recovery of Mouse Embryos Following 
Treatment with Ginsenoside Re. Two-cell embryos were flushed from the 
oviduct and placed into culture for 48 h with concentrations of ginsenoside Re 
equal to those found in the aqueous (A) and alcoholic (C) extracts. Treatment 
groups consisted of: 0, 0.6, 2.8, 14 and 55.9 µg/ml (A, B); 0, 0.9, 4.5, 22.4 and 
89.9 µg/ml (C, D). Embryos were then washed three consecutive times in 
KSOMaa and returned to culture in clean drops of culture media for 72 h (B, D). 
Embryos were categorized as being 2-cell, 4-cell, 8-cell, 8-cell compacted, 
morula or blastocyst after all time points. Progression on to the blastocyst stage 
was considered to represent full recovery from treatment. No significant 
differences were observed between treatment groups.  
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Figure 3.13 Morphology of Mouse Embryos Following Re Treatment. 
Comparative morphology of representative groups of embryos after 48 h 
treatment with concentrations of Re equal to those found in the aqueous (A-E) 
and alcoholic (F-J) ginseng extracts.  Treatment groups consisted of: 0 (A), 0.6 
(B), 2.8 (C), 14.0 (D) and 55.9 µg/ml (E); 0 (F), 0.9 (G), 4.5 (H), 22.4 (I) and 89.6 
µg/ml (J). Scale bars represent 100 µm.  
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Figure 3.14 Morphology of Mouse Embryos Following Recovery from Re 
Treatment. Comparative morphology of representative groups of embryos 
following recovery period with 0 µg/ml (A, B and K, L), 0.6 µg/ml (C, D), 2.8 
µg/ml (E, F), 14.0 µg/ml (G, H), 55.9 µg/ml (I, J), 0.9 µg/ml (M, N), 4.5 µg/ml (O, 
P), 22.4 µg/ml (Q, R) and 89.6 µg/ml (S, T) of ginsenoside Re for 24 (A-J) and 72 
hours (K-T). Scale bars represent 100 µm. 
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3.1.6 The Effect of Treatment with the Polysaccharide Fraction (PSF) on 
Preimplantation Development. 
Two-cell embryos from CD1 females were cultured for 48 hours in 0 
(control), 1.5, 7.5, 37.5 and 150 µg/ml of PSF. No significant differences in 
embryo development were identified when comparing preimplantation 
developmental progression between treatment groups (Figure 3.15A and 3.16A, 
D, G, J, M). Notably, after 48 h in treatment, a much higher percentage of 
embryos developed to the blastocyst stage for all groups than observed in all 
other previous experiments. This is likely due to the fact that embryos cultured 
with PSF were from CD1 and not MFI females that were used for all previous 
experiments.  CDI and MFIs are both outbred lines of mice that are commonly 
used to generate preimplantation embryos for research purposes. We have 
preferred MF1s simply because they display a more robust response to hormonal 
superovulation and thus allow for the collection of greater numbers of oocytes 
and embryos from fewer mice than CD1s do. No differences in development have 
been reported in the literature to date for embryos derived from these lines, 
however we have noted that CDI embryos do develop faster in vitro than MF1 
embryos. Our supplier of MF1 mice (Harlan Inc) has discontinued offering them 
due to the small number of labs around the world that use these mice. Thus we 
have had to shift exclusively to CD1 mice for all further experiments conducted in 
the lab. 
Embryos treated for 48 h with PSF were not affected by the treatment and 
developed normally. Once washed 3 consecutive times in KSOMaa and returned 
to culture in clean drops of culture media for 72 h, natural development continued 
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and no significant variations in blastocyst formation were noted between any 
treatment groups (Figure 3.15B and 3.16B, C, E, F, H, I, K, L, N, O). All data 
shown in Figure 3.15 is presented as the mean ± SD, representative of three 
independent replicates. Thus the overall conclusion from all of the single agent 
treatment experiments is that no single agent replicates the collective effects of 
AQ or ALC extract treatment observed on preimplantation development. Thus the 
negative impact on development observed from AQ and ALC treatment must 
stem from the collective effects of several of the ginseng extract components 
acting on the early embryo and restricting development. 
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Figure 3.15 Development and Recovery of Mouse Embryos Treated with 
PSF. Two-cell embryos were flushed from the oviduct and placed into culture with 
PSF. Treatment groups consisted of KSOMaa control (0 µg/ml), 1.5, 7.5, 37.5 
and 150 µg/ml and were cultured at 37°C under a 5% O2, 5% CO2 and 90% N2 
atmosphere for 48 h (A). Embryos were then washed three consecutive times in 
KSOMaa and returned to culture in clean drops of culture media for 72 h (B). 
Embryos were categorized as being 2-cell, 4-cell, 8-cell, 8-cell compacted, 
morula or blastocyst after all time points. Progression on to the blastocyst stage 
was considered to represent full recovery from treatment. No significant 
differences were observed between treatment groups.  
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Figure 3.16 Morphology of Embryos Following PSF Treatment. Comparative 
morphology of representative groups of mouse Two-cells after treatment for 48 h 
(A, D, G, J, M) and recovery for 24 h (B, E, H, K, N) and 72 h (C, F, I, L, O) with 
0 µg/ml (A, B, C), 1.5 µg/ml (D, E, F), 7.5 µg/ml (G, H, I), 37.5 µg/ml (J, K, L) and 
150 µg/ml (M, N, O) of PSF. Scale bars represent 100 µm. 
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3.2  Investigate the Combinatorial Effect of Ginsenosides Rb1, Rg1 and Re on 
Mouse Preimplantation Development in Vitro 
Two-cell embryos from CD1 females were cultured for 48 hours in 0 
(control), 2.6, 12.9, 64.3 and 257.1 µg/ml of a combinatorial solution of Rb1, Rg1 
and Re. No significant differences in embryo development were identified when 
comparing preimplantation developmental progression between treatment groups 
(Figure 3.17A and 3.18A, D, G, J, M). Notably, after 48 h in treatment, a much 
higher percentage of embryos developed to the blastocyst stage for all groups 
than observed in most other previous experiments. This is likely due to the fact 
that embryos cultured with the combinatorial solution were from CD1 and not MFI 
females that were used for the experiments outlined above. CDI embryos simply 
develop faster in vitro than MF1 embryos, which accounts for the higher 
blastocyst formation rate.  
Embryos treated for 48 h with a combination of Rb1, Rg1 and Re were not 
affected by the treatment, and developed normally. Embryos were then washed 
three consecutive times in KSOMaa and returned to culture in clean drops of 
culture media for 72 h. While blastocyst formation for embryos treated with 64.3 
µg/ml was reduced compared to embryos treated with 12.9 µg/ml, no significant 
variations in blastocyst development were observed between the control and any 
treatment groups at any time points throughout recovery (Figure 3.17B and 
3.18B, C, E, F, H, I, K, L, N, O). All data shown in Figure 3.17 is presented as the 
mean ± SD, representative of three independent replicates. Thus the overall 
conclusion from the experiment with the combinatorial ginseng solution is that the 
collective effects of AQ and ALC extract treatment observed on preimplantation 
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development are not due to this particular combination of ginsenosides. 
Therefore, the negative impact on development observed from AQ and ALC 
treatment must stem from a ginsenoside or non-ginsenoside compound that has 
not been investigated in this project, or the collective effects of several of the 
ginseng extract components acting on the early embryo and restricting 
development. 
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Figure 3.17 Development and Recovery of Mouse Embryos Treated with a 
Combinatorial Solution of Ginsenosides Rb1, Rg1 and Re. Two-cell embryos 
were flushed from the oviduct and placed into culture with a combination of Rb1, 
Rg1 and Re. Treatment groups consisted of KSOMaa control (0 µg/ml), 2.6, 12.9, 
64.3 and 257.1 µg/ml and were cultured at 37°C under a 5% O2, 5% CO2 and 
90% N2 atmosphere for 48 h (A). Embryos were then washed three consecutive 
times in KSOMaa and returned to culture in clean drops of culture media for 72 h 
(B). Embryos were categorized as being 2-cell, 4-cell, 8-cell, 8-cell compacted, 
morula or blastocyst after all time points. Progression on to the blastocyst stage 
was considered to represent full recovery from treatment. No significant 
differences were observed between treatment groups.  
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Figure 3.18 Morphology of Embryos Following Treatment with a 
Combinatorial Solution of Ginsenosides Rb1, Rg1 and Re. Comparative 
morphology of representative groups of mouse two-cells after treatment for 48 h 
(A, D, G, J, M) and recovery for 24 h (B, E, H, K, N) and 72 h (C, F, I, L, O) with 
0 µg/ml (A, B, C), 2.6 µg/ml (D, E, F), 12.9 µg/ml (G, H, I), 64.3 µg/ml (J, K, L) 
and 257.1 µg/ml (M, N, O) of a combinatorial solution of Rb1, Rg1 and Re. Scale 
bars represent 100 µm. 
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3.3 Determine the Safety of consuming both Ginseng Extracts on Pregnancy 
and Post-Partum Development in the Mouse 
The effects of treatment with AQ or ALC extract on mouse preimplantation 
development in vitro vary substantially from the reports of effects of treatment on 
mouse pregnancy and post-partum development using Red Korean ginseng. 
Thus it was essential to extend my studies and conduct in vivo experiments using 
North American ginseng to determine the effects, if any, of these extracts on 
pregnancy and post-partum development in the mouse. 
 
3.3.1 Females Gavaged with 50 mg/kg of Ginseng Extracts for Two Weeks 
prior to Mating and throughout Gestation.  
Female MF1 mice were placed into control (no gavage), sham (water 
gavage) and experimental treatments (gavage of 50 mg/kg of either AQ or ALC 
ginseng extract) each day for two weeks prior to mating and throughout 
gestation. 3-6 experimental replicates were carried out for each treatment group. 
Gestational day 0 was established by the presence of a vaginal plug after mating. 
Following parturition, the gestation period (average of 19 days for control) (Figure 
3.19A) and litter size (average of 12.75 pups per litter for control) (Figure 3.19B) 
were determined. Developmental growth was then assessed and pups were 
weaned and sexed on post-partum day 20. The percentage of males and females 
in each litter was compared between different treatment groups, and the sex ratio 
was determined (Figure 3.19C). No significant differences were observed 
between treatment groups for gestation period, litter size or sex ratio. 
 
 89
Pup growth rate was determined by weighing 247 individual pups every 
four days from birth to post-partum day 20. Differences in pup weight among the 
treatment groups were observed beginning on post partum day four. While none 
of these variations in growth were significantly different among the treatment 
groups, they persisted until day 20 post partum (Figure 3.20A). To determine 
whether the differences in development observed in Figure 3.20A are due to 
possible variations in growth rates amid males and females, weight was recorded 
according to sex on day 20. There were no significant differences in male pup 
weight on post-partum day 20 between any treatment groups (Figure 3.20B). 
However, pup weight did vary significantly between the control (average of 14.1g) 
and ALC (average of 13.3g) groups of female pups on post-partum day 20 
(Figure 3.20C). All data shown in Figure 3.19 and 3.20 are presented as the 
mean ± SD. 
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Figure 3.19 The Effect of Pre-Pregnancy and Gestational Ginseng 
Treatment (50 mg/kg) on Pregnancy and Post-Partum Development. Female 
MF1 mice were placed into control (no gavage), sham (water gavage) and 
experimental treatments (gavage of 50 mg/kg of either AQ or ALC ginseng 
extract) for two weeks prior to mating and throughout gestation. Following 
parturition, gestation period in days (A) and number of pups per litter (B) were 
determined for each female. Pups were then sexed on post-partum day 20 and 
the percentage of males vs. females in each litter was evaluated (C). Differences 
in gestation period, litter size and sex ratio between treatment groups are 
presented as the mean ± SD, representative of 3-6 independent replicates. No 
significant differences were observed between treatment groups.  
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Figure 3.20 The Effect of Pre-Pregnancy and Gestational Ginseng 
Treatment (50 mg/kg) on Post-Partum Pup Weight and Growth. Female MF1 
mice were placed into control (no gavage), sham (water gavage) and 
experimental treatments (gavage of 50 mg/kg of either AQ or ALC ginseng 
extract) for 20 weeks prior to mating and throughout gestation. Following 
parturition, pups were individually weighed every four days until weaning on post-
partum day 20 (A). Once weaned, pups were sexed and weight was recorded 
according to sex in order to determine differences between male (B) and female 
(C) developmental weight gain between treatment groups. Differences in pup 
growth between treatment groups are presented as the mean ± SD, 
representative of 49-77 (A) and 3-6 (B, C) independent replicates. Significant 
differences are represented by different superscripts (P≤0.05).  
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3.3.2 Females Gavaged with 500 mg/kg of Ginseng Extracts for Two Weeks 
prior to Mating and throughout Gestation. 
 Female MF1 mice were placed into control (no gavage), sham (water 
gavage) and experimental treatments (gavage of 500 mg/kg of either AQ or ALC 
ginseng extract) each day for two weeks prior to mating and throughout 
gestation. 3-6 experimental replicates were carried out for each treatment group. 
Gestational day 0 was established by the presence of a vaginal plug after mating. 
Following parturition, significant (p<0.05) variations in gestation period were 
noted between the control and both AQ and ALC groups, with a difference of 0.78 
and 1 day respectively. Furthermore, a significant difference (p<0.05) of 0.68 
days was observed between the sham and ALC groups (Figure 3.21A). The 
average number of pups per litter between treatment groups also varied 
significantly (p<0.05) between the control (15.03 pups per litter) and sham (12 
pups per litter) treatments, supporting our observation that gavage can influence 
gestation period (Figure 3.21B). No significant differences in sex ratio were 
detected in any of the treatment groups on day 20 post-partum (Figure 3.21C).  
To evaluate pup growth and development, 212 individual pups were 
weighed every four days from birth to post-partum day 20. No significant 
differences (p<0.05) were observed in pup weight among treatment groups until 
post-partum day 20. On day 20 post-partum there was a significant (p<0.05) 
difference between the ALC treatment and the three other groups (control, sham 
and AQ) (Figure 3.22A). To determine whether the observed differences in 
weight were due to possible variations in growth between males and females, 
weight was determined for each sex on day 20. A significant difference (p<0.05) 
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in male pup weight was observed on post-partum day 20 between the sham 
(mean = 13.4g) and ALC (mean = 15g) groups (Figure 3.22B). However, no 
significant differences in female pup weight on post-partum day 20 were 
observed between any treatment groups (Figure 3.22C). All data shown in Figure 
3.21 and 3.22 are presented as the mean ± SD. Overall the results support a 
cautionary approach to determining whether ginseng extract consumption has a 
negative influence on pregnancy and post-partum development. Gavaging 
certainly has major influence on gestation term and litter size, however 
independent effects of AQ and ALC extracts on gestation period and pup growth 
were also observed. In addition, the effects of ginseng consumption display some 
signs of gender bias, especially on weight gain.   
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Figure 3.21 The Effect of Pre-Pregnancy and Gestational Ginseng 
Treatment (500 mg/kg) on Pregnancy and Post-Partum Development. 
Female MF1 mice were placed into control (no gavage), sham (water gavage) 
and experimental treatments (gavage of 500 mg/kg of either AQ or ALC ginseng 
extract) for two weeks prior to mating and throughout gestation. Following 
parturition, gestation period in days (A) and number of pups per litter (B) were 
determined for each female. Pups were then sexed on post-partum day 20 and 
the percentage of males vs. females in each litter was evaluated (C). Differences 
in gestation period, litter size and sex ratio between treatment groups are 
presented as the mean ± SD, representative of 3-6 independent replicates. 
Significant differences are represented by different superscripts (P≤0.05). 
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Figure 3.22 The Effect of Pre-Pregnancy and Gestational Ginseng 
Treatment (500 mg/kg) on Post-Partum Pup Weight and Growth. Female 
MF1 mice were placed into control (no gavage), sham (water gavage) and 
experimental treatments (gavage of 500 mg/kg of either AQ or ALC ginseng 
extract) for two weeks prior to mating and throughout gestation. Following 
parturition, pups were individually weighed every four days until weaning on post-
partum day 20 (A). Once weaned, pups were sexed and weight was recorded 
according to sex in order to determine differences between male (B) and female 
(C) developmental weight gain between treatment groups. Differences in pup 
growth between treatment groups are presented as the mean ± SD, 
representative of 27-66 (A) and 3-6 (B, C) independent replicates. Significant 
differences are represented by different superscripts (P≤0.05).  
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Discussion 
 
4.1 Concentration Response Effect of the Aqueous and Alcoholic Ginseng 
Extracts derived from North American Ginseng on Mouse Preimplantation 
Development in Vitro. 
Ginseng is a natural herbal product and its consumption and inclusion as 
part of a healthy diet is on a dramatic rise worldwide. Due to the many purported 
health benefits associated with this herb, it is one of 10 most commonly used 
herbal medicines in the United States (Bent and Ko 2004). Women are the 
predominant users of herbal medicines (MacLennan et al. 1996; Eisenberg et al. 
1998; Ernst and White 2000). In a US survey, 9.1% of pregnant women declared 
the use of these products during their current pregnancy (Gibson et al. 2001). In 
China, as high as 15% of women consumed ginseng during pregnancy with the 
primary reason being that it is believed to be “good for pregnancy and the fetus” 
(Ong et al. 2005). Due to the lack of information on the safety of ginseng 
consumption during pregnancy, its effects on preimplantation development, 
pregnancy and post-partum development were assessed in this present study. In 
summation, it was discovered that AQ and ALC ginseng extract treatments 
caused a concentration dependent inhibition of development when applied 
directly to preimplantation embryos in culture. Experiments were repeated with 
individual ginsenosides, and ginsenosides Rb1 and Rg1 reduced the number of 
embryos progressing to the morula stage at low concentrations. Importantly, 
pregnancy and post-partum development were affected with an orally 
administered high dose of 500 mg/kg of North American ginseng (NAG) extracts. 
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This study indicates that direct exposure to ginseng extracts is detrimental to the 
completion of normal early mammalian development. 
The effect of ginseng and ginsenosides on postimplantation embryos has 
been examined (Chan et al. 2003, 2004; Liu et al. 2005a, 2005b, 2006; Lee et al. 
2008), however its direct influence on preimplantation embryo development and 
thus embryo implantation, has not been investigated to date. Furthermore, most 
experiments determining ginseng’s effect on reproduction were undertaken with 
Korean or Chinese ginseng. North America is known to now produce some of the 
most potent forms of ginseng, and this is becoming an important agricultural crop 
as well as a sought after herbal medicine. It is thus essential that research 
investigate the safety of NAG on reproduction and pregnancy. Furthermore, due 
to such differences in composition between the AQ and ALC extracts (as 
previously described), it is important to investigate both extracts separately. In 
this present study, the effects of AQ and ALC extracts derived from North 
American ginseng, as well as the influence of its individual active compounds on 
preimplantation development in the mouse were assessed. Treatment with the 
AQ ginseng extract resulted in a concentration-dependent inhibition of 
development after 48 h in culture. Treatment with the lowest concentration of 10 
µg/ml of AQ extract did not affect embryo development, however 50, 250 and 
1000 µg/ml AQ extract levels increasingly halted development at the two-cell and 
four-cell stages. Furthermore, recovery potential was extremely low for these 
three treatments and a significant blockade of blastocyst development was 
observed. Treatment with the ALC extract produced similar outcomes. The main 
variation between treatments with the two types of extracts was observed with 
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the 1000 µg/ml ALC concentration.  It is challenging to understand the 
mechanistic basis for the observed difference in outcomes using the 1000 ug/ml 
concentration of both ginseng extracts, however one main difference between 
both extracts is that the ALC extract contains twice the levels of ginsenosides as 
the AQ extract. We have very little understanding regarding the precise 
mechanism for ginseng extract action on any cell system, including the early 
embryo. However, my outcomes from the ALC extract experiment are 
reminiscent of several types of ligand/receptor interactions where high levels of 
ligand result in receptor desensitization and loss of ligand treatment effects. Of 
course this is speculation and requires a great deal more research to fully 
understand, but it may be possible that the highest ALC concentration did not 
impair development simply because of concentration effects on cell 
ligand/receptor signaling systems. The identity of those ligand/receptor 
interactions requires extensive new research to uncover them. 
In addition each extract has a unique composition. For example, the AQ 
extract has less Rb1, Rb2, Rc, Rd and Re, has greater levels of Rg1, and is 
composed of 15% PS, whereas the ALC extract does not contain PS. Due to the 
complex composition of ginseng products, the precise compound and mechanism 
causing the blockade in development is not known, but certainly should become 
a focus for further research in this area. Thus the active ingredient halting 
embryonic development and causing the different outcomes observed for both 
extracts may not necessarily be due to a specific ginsenoside or PS but to other 
compounds found in the extract as well as a possible combination of certain 
composites. Finally, excluding embryos treated with 250 µg/ml, all other groups 
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treated with the ALC extract recovered from the 48 h treatment and progressed 
onto the blastocyst stage after 72 h recovery. The fact that embryonic 
development was not as severely affected by ALC treatment as that observed 
with the AQ extract may have provided these embryos with a better opportunity to 
offset any negative treatment effects and continue their normal progression to the 
blastocyst stage once removed from treatment.  
As previously mentioned, the ALC ginseng extract has double the 
concentration of ginsenosides as the AQ extract.  Embryos were treated with 
2000 µg/ml of the AQ ginseng extract, which has the same total ginsenoside 
concentration as 1000 µg/ml of ALC, in order to determine whether the lack of 
influence imparted by ALC treatment at this concentration was due to a protective 
benefit of high ginsenoside levels. However, the ALC outcomes were not 
replicated in this experiment, and instead of observing no negative effect on 
development from the AQ extract, treatment effects were amplified and none of 
the embryos treated with 2000 µg/ml developed to the morula or blastocyst 
stages as all were halted at the two-cell and four-cell stages. Furthermore, none 
of the embryos recovered from this treatment. Taken together, these results 
suggest that the absence of an effect on embryonic development with 1000 µg/ml 
of ALC is not simply due to higher total ginsenoside concentrations, but likely due 
to a combination of composites or non-ginsenoside compounds distinct from that 
found in the AQ extract. In conclusion, the detrimental effect observed on 
embryonic development induced by treatment with the AQ and ALC ginseng 
extracts is concentration dependent, and direct embryo exposure to ginseng 
extracts is embryotoxic and thus detrimental to preimplantation development. 
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Furthermore, once removed from treatment, embryo recovery is limited if possible 
at all, and most embryos are not able to resume development once halted at the 
two-cell and four-cell stages.  
 
4.2 Concentration Response Effect of the Polysaccharide Fraction and 
Individual Ginsenosides Rb1, Rg1, and Re on Mouse Preimplantation 
Development in Vitro. 
 My subsequent experiments focused on attempting to define the primary 
constituents of the ginseng extracts that were impeding preimplantation 
development in vitro. The exact compound(s) responsible for the embryonic 
developmental delay observed with the AQ and ALC ginseng extracts have yet to 
be identified due to the complexity of the ginseng plant and all the products 
derived from it. Due to the fact that ginsenosides are the major bioactive 
component in ginseng and so much research has been centered around their 
effects on reproduction (Chan et al. 2003, 2004; Liu et al. 2005a, 2005b, 2006; 
Lee et al. 2008), embryos were treated with individual ginsenosides Rb1, Rg1 
and Re in order to determine their individual effect on preimplantation 
development. Each ginsenoside has a unique chemical structure, which is the 
foundation for their different pharmacological and physiological effects in the 
body (Sievenpiper et al. 2003). Experiments conducted with Rb1 (PD), Rg1 and 
Re (PT) also assured that both major ginsenoside groups, protopanaxadiols and 
protopanaxatriols (Tawab et al. 2010) were being tested. In addition, these 
ginsenosides are extensively researched due to high concentrations found in 
most ginseng species, including AQ and ALC extracts, which made them an ideal 
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starting point for assessing the primary constituents of the ginseng extracts that 
could be impeding preimplantation development in vitro. 
 Rb1 is the major ginsenoside found in North American Ginseng (NAG) and 
is representative of the PD group (Tawab et al. 2010). Previous studies have 
investigated the direct effect of ginsenoside Rb1 on organogenesis in 
postimplantation embryos, and have reported that Rb1 treatment significantly 
reduces the total morphological scores of rat and mouse embryos when using 
concentrations ≥ 30 µg/ml. In addition, the detrimental effect on morphogenesis 
was concentration dependent (Chan et al. 2003; Liu et al. 2005). In my study, 
preimplantation embryos treated with Rb1 displayed a reduced rate of 
development to the morula stage when compared to the control. However this 
effect was not concentration dependent and was only observed with a low 
concentration of 8.2 µg/ml. Furthermore, all embryos recovered from treatment 
and progressed to the blastocyst stage.  
 Rg1 is found in highest concentrations in the AQ ginseng extract derived 
from NAG and is representative of the PT group. Liu et al. 2006 investigated the 
effect of Rg1 on postimplantation embryos, and found that it remarkably 
decreased the total morphological score of mouse and rat embryos when 
concentrations of 30 and 50 µg/ml were tested. Furthermore, postimplantation 
embryonic growth was affected using concentrations as low as 10 µg/ml. In my 
present study however, the only significant difference in development was 
observed between the control and embryos treated with 0.03 µg/ml of Rg1. 
Furthermore, while blastocyst formation was delayed for groups treated with 0.03 
and 0.15 µg/ml during recovery, all embryos recovered from treatment after 72 h 
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in culture. In contrast to Liu et al. 2006, the embryonic developmental delay was 
not concentration dependent and was only observed in the 0.03 µg/ml treatment. 
Future studies investigating the effects of Rg1 on early development should 
consider the use of higher concentration treatments. Thus my study certainly 
varied from the outcomes presented in the Liu et al. 2005 and 2006 studies 
showing effects of Rb1 and Rg1 treatment on postimplantation development, as I 
only observed treatment effects on preimplantation embryos using lower 
concentrations of either ginsenoside, and the effects were not concentration 
dependent. I obtained the individual Rg1 and Rb1 ginsenosides from Sigma 
chemical company, and it is advertised to be a highly purified form of each 
ginsenoside. It is possible the purity of the ginsenoside samples varied between 
my study and Liu et al 2005 and 2006, which may account for the variation in 
outcomes between the studies. Even though I observed some restriction of 
development with low concentrations of Rb1 and Rg1, the fact that all embryos 
readily recovered from treatment and demonstrated a normal progression to the 
blastocyst stage lead me to conclude that treatment with Rb1 or Rg1 alone does 
not replicate the outcomes observed following treatment with complete AQ or 
ALC extracts on preimplantation development. 
 Re is the second most prominent ginsenoside found in NAG extracts and 
is representative of the PT group. According to Chan et al. 2004, Re exerts a 
strong postimplantation embryotoxic effect starting with concentrations of 50 
µg/ml. Re treatment severely disrupted development and was associated with a 
significant reduction in the morphological scores of rat post implantation embryo 
development (Chan et al. 2004). Contrastingly, when evaluating the effect of 
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ginsenoside Re on preimplantation development in vitro, no significant delays in 
embryonic development between the control and any treatment groups were 
found, even for high concentrations up to 89.6 µg/ml.   
 Finally, the influence of the PSF separated from the AQ ginseng extract on 
preimplantation development has not been investigated until now. In my present 
study, the effect of five different concentrations of PSF after 48 h in culture was 
determined. No significant inhibition of embryonic development was observed, 
even for concentrations up to 150 µg/ml. All treated embryos developed naturally 
and progressed to blastocyst stage once the extract was washed out and 
embryos were placed into fresh medium for 72 h. Thus the overall conclusion 
from all of the single agent treatment experiments is that while treatment with 
ginsenoside Rb1 and Rg1 using low concentrations certainly halted 
preimplantation development, neither these effects or the effect of treatment with 
Re or PSF negatively affected development overall.  Therefore no single 
ginsenoside replicated the collective effects of AQ or ALC extract treatment 
observed on preimplantation development. Thus the impact on preimplantation 
development observed from AQ and ALC treatment must either result from an 
individual non-ginsenoside component not yet identified and experimented with or 
the collective effects of several of the ginseng extract components acting on the 
early embryo and impeding healthy embryonic development.  
 
4.2 The Combinatorial Effect of Ginsenosides Rb1, Rg1 and Re on Mouse 
Preimplantation Development in Vitro 
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My subsequent experiments focused on attempting to define whether a 
combinatorial solution of ginsenosides could be responsible for the 
developmental blockade observed when preimplantation embryos were directly 
exposed to AQ and ALC ginseng extracts in vitro. As previously shown, individual 
ginsenoside and PSF treatment did not replicate the effects observed when 
embryos were treated with whole extracts. Thus a combinatorial solution of Rb1, 
Rg1 and Re was used to treat the embryos for 48 h, in order to determine 
whether the developmental delay was due to the additive effects of a combination 
of ginsenosides. The effect of a combination of Rb1, Rg1 and Re on 
preimplantation development and reproduction has not been investigated until 
now. In my study, embryos were cultured with five different concentrations of the 
combinatorial solution for 48 h. No significant inhibition of embryonic 
development was observed for concentrations up to 257.1 µg/ml. Furthermore, all 
treated embryos developed naturally and progressed to the blastocyst stage once 
the extract was washed out and embryo was placed into fresh medium for 72 h. 
Thus the overall conclusion from this experiment is that treatment with a 
combination of ginsenosides Rb1, Rg1 and Re did not replicate the collective 
effects of AQ or ALC extract treatment observed on preimplantation 
development. Thus the impact on preimplantation development observed from 
AQ and ALC treatment must either result from a non-ginsenoside component not 
yet identified and experimented with or the collective effects of several of the 
ginseng extract compounds acting on the early embryo and impeding healthy 
embryonic development. Future experiments should be directed at determining 
the origin of the effects of ginseng extract treatment on preimplantation 
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development, even if oral consumption and in vivo studies do not indicate that 
ginseng consumption is detrimental to pregnancy and post-partum development.  
 
4.4 Determine the Safety of Consuming both Ginseng Extracts on Pregnancy 
and Post-Partum Development in the Mouse 
My results are the first to indicate that direct exposure to ginseng extracts 
is detrimental to preimplantation development. These outcomes are in sharp 
contrast to findings from in vivo studies investigating the influence of Red Korean 
Ginseng treatment two weeks before mating and throughout gestation on 
pregnancy in the mouse (Shin et al. 2010). It was determined that embryonic 
implantation and fetal growth were not negatively affected (Shin et al. 2010).  Due 
to these discrepancies in outcomes between my culture study and Shin et al. 
2010, it was essential to conduct in vivo experiments using NAG to determine the 
effects, if any, of these extracts on pregnancy and post-partum development in 
the mouse. Furthermore, since there are usually dose limitations in human 
studies, a lower cdose of 50 mg/kg as well as an extremely high dose of 500 
mg/kg (≈ 50 times the clinical recommended daily dose by KFDA) were 
investigated.  
 The first experiment consisted of treatment with 50 mg/kg of NAG extracts. 
Following parturition, the gestation period and litter size were determined as well 
as the sex ratio of mice weaned on post-partum day 20. No significant differences 
were observed between any treatments. Lastly, pup growth rate was determined 
by weighing individual pups every four days from birth to post-partum day 20 and 
no significant differences were observed between groups. In the second 
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experiment, females were gavaged with 500 mg/kg of ginseng extracts for two 
weeks prior to mating and throughout gestation. Interestingly, a significant 
difference of 0.68 days was observed between the sham and ALC group for 
gestation period.  This difference of 0.68 days in mouse gestation would translate 
into nearly 9.5 days difference if a comparable effect were observed in humans. 
The average number of pups per litter between treatment groups also varied 
significantly between the control and gavaged treatments, implying that the 
gavage procedure certainly had some potential for affecting litter size. No 
significant differences in sex ratio were detected in any of the treatment groups. 
Additionally, pup growth rates from birth to post partum-day 20 were evaluated, 
and no developmental variations were observed in pup weight among treatment 
groups until post-partum day 20, where a significant difference between the ALC 
treatment and the three other groups (control, sham and AQ) was observed. To 
determine whether the observed difference in weight was due to possible 
variations in growth between males and females, weight was determined for each 
sex on day 20. While no differences were observed between treatment groups for 
female weight, a significant difference in male pup weight was observed on post-
partum day 20 between the sham and ALC groups, indicating that pup growth 
rate differences may have been primarily due to variations in male weight, and 
not female growth. These results indicate that in vivo ALC ginseng treatment at 
very high dose of 500 mg/kg throughout gestation affect gestation period and 
also pup post-partum growth.  
Thus, clear differences between administration of 50 and 500 mg/kg of 
both ginseng extracts were observed. It seems that while treatment with a low 
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dose does not affect pregnancy and post-partum development in vivo, a high 
dose of 500 mg/kg of the ALC ginseng extract does increase gestation period 
and pup growth rates. The importance of these doses is uncertain. Most 
recommended levels for ginseng product consumption range from 1-2 g per day, 
indicating that a 100 kg person would have to ingest 50 g of ginseng daily to 
equal the 500 mg/kg level that I gavaged. Thus, even the 50 mg/kg/day is still 
high, however it is much closer to realistic consumption levels. In addition, my in 
vivo results contrast dramatically with the effect of NAG on preimplantation 
embryos. This may be due to the fact that the preimplantation embryos were 
directly exposed to the ginseng extract in culture, whereas concentrations of 
ginseng directly affecting embryos in vivo are unknown due to uncertainties 
regarding ginseng compound absorption, metabolism and renal clearance rate 
after consumption in the human. It is very likely that oral consumption results in 
very little if any embryonic exposure to ginseng compounds in the reproductive 
tract. The levels that could accumulate in the reproductive tract for any species 
are simply not known.  
Studies have determined however, that maximum concentrations of Rb1, 
Rg1 and Re in rat plasma after an oral administration of 10 and 300mg/kg of 
ginseng powder were between 1.51 to 6.42 ug/ml (Li et al. 2007a). However, 
when Shin et al. 2010 attempted to measure Rb1 and Rg1 plasma concentrations 
in pregnant mice, no trace of these ginsenosides were found following oral 
treatment with an extremely high dose of 2000mg/kg/day of Red Korean ginseng 
after 30 min and 2h. Whether these results are transferable to humans, and intact 
ginsenosides are absorbed by the gastrointestinal tract and reach the systemic 
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circulation before first being metabolized is unknown. These results indicate that 
ginsenoside pharmacokinetics is poorly understood in general. The 
pharmacokinetics of ginseng extracts and placental transfer of ginsenosides in 
humans must be investigated further, but short half-life, poor absorption and rapid 
clearance may all contribute to very low exposure levels in the reproductive tract 
and could provide reasonable understanding as to why ginseng treatments differ 
so much with regards to effects to early development when comparing in vitro 
and in vivo treatment regimes. 
Overall the results support a cautionary approach to determining whether 
ginseng extract consumption has a negative influence on pregnancy and post-
partum development. Treatment with 50 mg/kg of NAG ginseng extract does not 
negatively affect pregnancy and post-partum development in the mouse. 
However, 500 mg/kg/day, certainly has an influence on litter size, and 
independent treatment with the ALC extract increases gestation period and pup 
growth when compared to the sham group. While my results with high levels of 
NAG do not agree with the outcomes from experiments using Korean Red 
ginseng, both studies did not observe a negative impact from administration of 
low levels of ginseng on pregnancy and post-partum development. While different 
experimental designs could be attempted, such as gavaging females before 
pregnancy only or throughout gestation only, and more experimental replicates 
could be added in order to increase the overall power of the study, it can be 
cautiously concluded that it is unlikely that oral consumption of ginseng at typical 
daily levels would negatively affect pregnancy and post-partum development in 
the mouse 
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4.5 Conclusions 
 
In conclusion, my study has revealed the following regarding ginseng 
extract effects on preimplantation development in culture and pregnancy and 
post-partum development in the mouse. 
1. Treatment with either AQ or ALC NAG extracts results in a concentration 
dependent blockade of preimplantation development in vitro. 
2. Treatment with 1000 ug/ml ALC extract does not negatively affect 
preimplantation development in vitro. 
3. Preimplantation embryos treated with ALC extract are more likely to 
recover from treatment than embryos treated with AQ extract however, 
overall recovery from treatment is low for almost all treatments. 
4. Treatment with Rg1, Rb1, Re and PSF alone does not replicate the effect 
of treatment with full AQ or ALC extract on preimplantation development. 
5. Oral administration of 50 mg/kg/day AQ or ALC extract does not affect 
gestation, litter size, sex ratio or post-partum growth in the mouse. 
6. Oral administration of 500 mg/kg/day AQ or ALC extract does affect 
gestation period and pup growth rate. 
7. It is likely that oral consumption of typical daily levels of ginseng will not 
adversely affect pregnancy and post-partum development, which is 
probably due to a very low ginseng accumulation in the reproductive tract 
and thus low embryonic exposure to ginseng extract in vivo. 
8. Future experiments should be directed towards determining ginseng 
extract metabolism, clearance rate and reproductive tract levels. 
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9. The mechanisms underlying the effects of ginseng treatment on 
preimplantation development in vitro should be investigated. 
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